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CHAPTER 1. GENERAL INTRODUCTION 
Introduction 
Since 1989, the study of isoprenoid-modified (prenylated) proteins has emerged as an 
extremely active area of research due to the great potential for novel therapeutic applications, as 
many prenylated proteins play prominent roles in cancer biology, viral and microbial 
infections, and other disease states. The numbers and types of proteins that are modified on 
their C-termini with 15 or 20 carbon isoprenoids continues to expand, and as the list of 
prenylated proteins grows, so does the potential for pharmacological intervention. Thus, it is 
imperative that research continues into both the basic mechanisms governing protein 
prenylation, as well as the subsequent biological consequences of this modification. 
The work presented in this dissertation describes a novel aspect of prenylation - one in 
which a protein (mGBPl) fails to be prenylated. The mechanism behind this lack of 
prenylation appears to involve contributions from both N- and C-terminal regions of mGBPl, 
and as such represents a previously unrecognized means of cellular regulation of prenylation. 
A complete understanding of this unique mechanism may lead to the development of new 
compounds for the treatment of cancer and other diseases. 
Dissertation Organization 
This first chapter of the dissertation will detail the current status of what is known 
regarding the mechanisms and processing events associated with protein prenylation as well as 
the biological effects this class of modiHcation can have on the various proteins to which it is 
attached. Additionally, the potential benefits and shortcomings of preventing cellular 
prenylation in the treatment of diseases will also be discussed as will our model system for 
studying novel aspects of prenylation (Guanylate Binding Proteins). 
Chapter 2, which has been submitted for publication in the journal Molecular Biology 
of the Cell, is the initial characterization of the prenylation of murine Guanylate Binding 
Protein-1 (mGBPl). The main fmding of this paper was the surprising defect in isoprenoid 
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attachment to mGBPl in vivo, even though this protein possesses a suitable CaaX motif at its 
C-terminus. Our initial mutational analysis of mGBPl showed that amino acids within its C-
terminus play a role in preventing efficient modification by geranylgeranyl transferase I 
(GGTase I). 
The third chapter, to be submitted to the Journal of Biological Chemistry, extends the 
initial findings of Chapter 2 by demonsu-ating that the observed difficulty in the prenylation of 
mGBPl seen in cells also occurs in in vitro conditions and therefore does not result from 
difficulties in cellular metabolism of isoprenoids or prenyl transferase inaccessibility, but 
instead, must arise from an intrinsic property of mGBPl itself. We also show in Chapter 3 
that the C-terminus of mGBPl is an acceptable substrate for prenylation when it is removed 
from the context of the native protein, thus implicating the body of mGBPl as an inhibitory 
regulator of prenylation of the C-terminus. Removal of various internal domains of mGBPl 
revealed that the N-terminal region possessing the GTP-binding domain strongly participates in 
blocking geranylgeranylation of the C-terminal CaaX motif. This highly unexpected finding 
demonstrates that mGBPl represents a new example in the field of protein prenylation whereby 
a GTP-binding domain can negatively influence CaaX motif utilization. 
Chapter 4 will present the general conclusions drawn from this work as it applies to the 
field of protein prenylation. 
Literature Review 
INTRODUCTION TO PROTEIN PRENYLATION 
Naturally occurring covalent modification of peptides by isoprenoids was first 
described over twenty years ago for a mating factor from the fungus Rhodosporidium 
toruloides (61). However, because researchers were unaware of cellular signal sequences for 
prenylation, similar modification of eukaryotic proteins remained largely ignored for over a 
decade. Not until the Ras family of proteins was shown to be prenylated (48) with famesyl 
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isoprenoids (17) did the scientific community turn their full attention to this novel post-
translational protein modiHcation. 
Famesyl (15 carbons) and geranylgeranyl (20 carbons) isoprenoids are found in C-
terminal thioether linkages with cysteine residues in approximately 2% of all cellular proteins 
(34) (for reviews of prenylation, see (16,42, 83, 138)). The enzymes that attach these lipids 
are grouped into two classes. The first, diose of the CaaX prenyl transferases, catalyze the 
prenylation of proteins possessing a CaaX motif as their final four amino acids. These 
enzymes, and their potential substrates, will form the focus of the review and also the 
subsequent data chapters. The second class of enzyme, Rab geranylgeranyl transferase 
(GGTase 11), geranylgeranylates the Rab family of GTPases and will not be discussed. 
The CadX motif refers to the final four amino acids of a protein where C stands for the 
cysteine to be prenylated, followed by two generally aliphatic (a) amino acids and the final 
amino acid of the protein, X. The existence of this motif was first hypothesized as researchers 
began to compare the C-termini of known prenylated proteins (38). However, confirmation of 
the "CaaX hypothesis" as a cellular signal for prenylation arrived after the first prenyl 
transferase was purified and shown to be active on peptides of only 4 amino acids in length 
(102). Further work showed that although the nature of the a residues can influence the 
efficiency of prenylation and additional CaaX processing (62, 87), specificity for which 
isoprenoid will be attached resides in the final amino acid X (67, 87, 104). This is achieved 
through specific recognition by either famesyl transferase (FTase) or geranylgeranyl 
transferase I (GGTase I). FTase has been shown to prefer CaaX proteins terminating most 
commonly in Met, Ser, Ala, or Gin whereas GGTase I preferentially recognizes and 
prenylates CaaX motifs ending with Leu or Phe. In both cases, efficiency of FTase and 
GGTase I-mediated modification is assumed to be near 100% based on mass-spectrometric 
analysis of CooX-containing proteins (37,78,96). 
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FTase and GGTase I are distinct but related homodimeric enzymes of a and P subunits 
with the a subunit being conmion to both enzymes (138). Due to the shared subunit, it was 
hypothesized early on that the p subunit would provide for subsu-ate specificity (103). Indeed, 
biochemical characterization has shown that the P subunits are primarily responsible for the 
selection of the appropriate lipid and CaaX substrates (27,73,119). However, mutational and 
photolabeling experiments have also demonstrated a clear role for the a subunit in catalysis (4, 
98, 135), prompting researchers to speculate that both subunits participate in catalyzing the 
prenylation reaction. These speculations were conHrmed after the crystal structure of the FTase 
holoenzyme was solved (97). This structure showed the existence of an active site cleft at the 
o/p subunit interface. Subsequent co-crystal structures of FTase with lipid, or lipid and 
peptide substrate, bound (79, 117) showed that a hydrophobic pocket within the P subunit is 
responsible for binding the appropriate isoprenoid whereas protein substrate binding is 
accomplished by residues from both subunits. 
The presence of an isoprenoid-binding pocket has lead to the "molecular ruler" 
hypothesis for lipid specificity (97). The depth of the isoprenoid-binding pocket of FTase is 
such that only famesyl pyrophosphate is the correct length for the CI isoprenoid carbon to be 
in register with the CaaX cysteine during catalysis. This information gives a mechanistic 
explanation for previous results showing that FTase could bind famesyl and geranylgeranyl 
pyrophosphate with similar efficiencies, but only famesyl could be utilized for the prenylation 
reaction (101). The mechanism by which GGTasel preferentially utilizes geranylgeranyl 
pyrophosphate is currently unknown, but it is clear that GGTase I does have a distinct 
preference for geranylgeranyl, as the C20 isoprenoid binds 300 times tighter than famesyl 
(137). 
A structural explanation as to how FTase and GGTase I selectively identify CaaX-
containing proteins, and the subsequent discrimination of CIS vs. C20 substrates based on the 
CaaX 'X, also remains a mystery. However, it is clear that the choice of an appropriate CaaX 
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substrate by a prenyl transferase is dictated predominantly by the p subunit even though, as 
previously mentioned, both the a and P subunits of FTase and GGTase I contribute to the 
binding of protein substrates. Mutational studies of the P subunit of FTase show that single 
point mutations can be made that allow for binding and famesylation of proteins with GGTase-
specific CaaX motifs (27). It is believed that steric factors contribute to this change of CaaX 
acceptance, as the size of the substituted amino acid within FTase appeared to be the main 
factor influencing the ability to famesylate a GGTase-specific CaaX. Similar changes in 
substrate specificity (i.e. famesylation of a C20-type CaaX) are seen when the active site zinc 
atom of wild type FTase is replaced with a cadmium atom (139). In this example, changing the 
type of metal ion may also change steric factors within, or perhaps change the local geometry 
of, the active site. Even though the aforementioned FTase P subunits retained preference for 
the famesyl isoprenoid, other studies have suggested that the type of isoprenoid (CIS vs. C20) 
bound to the prenyl transferase may also play a role in CaaX motif selection in the wild type 
prenyl transferases (15). Therefore, until further biochemical and structural work is 
performed, the mechanisms governing choice of CaaX substrates by FTase and GGTase I will 
not be known in complete detail. 
ENZYMOLOGY OF PROTEIN PRENYLATION 
The reaction pathways governing the binding of substrates for both FTase and 
GGTase I have been investigated at great length (29, 40, 116, 141). For both enzymes, 
substrate binding follows an ordered pathway, with isoprenoid association preceding the 
binding of CaaX substrate. Release of prenylated protein is the rate-limiting step in the reaction 
for both enzymes (40, 137). This may have biological significance, as it has been shown that 
for FTase, famesyl pyrophosphate binding is required for the release of prenyl product (120). 
These authors have hypothesized that release of prenylated protein from prenyl transferases (at 
least for FTase) could be a regulated event based on the availability and cellular location of 
isoprenoid pyrophosphates. 
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Although there is good agreement as to the reaction order for both FTase and 
GGTase I, the precise mechanism behind formation of the thioether linkage between 
isoprenoid and CaaX cysteine remains a topic of debate. Both electrophilic (18, 30) and 
nucleophilic (39, 52,54) mechanisms have been suggested. Although a consensus has not yet 
been reached, the evidence supports a model in which perhaps both electrophilic activation of 
the isoprenoid (through a carbocation intermediate) as well as nucleophilic activation of the 
CaaX cysteine (through zinc-mediated thiolate formation) play a role in formation of the 
thioether bond. 
PROCK.SSING OF PRENYLATED PROTEINS 
Once a CaaX protein has been prenylated, subsequent enzymatic processing of the C-
terminus then occurs (36). Proteolysis of the final three amino acids {aaX), followed by 
carboxymethylation of the newly exposed prenylcysteine C-terminus, is believed to occur 
immediately following prenylation of all CaaX proteins (for exceptions, see (51, 108)). The 
protease and carboxymethyltransferase responsible for catalyzing these reactions are both 
localized in vivo to the endoplasmic reticulum (26, 95). Because prenyl transferases are 
soluble enzymes, newly prenylated proteins must be shuttled to the endoplasmic reticulum for 
further enzymatic processing. This has lead to the speculation that perhaps the prenyl 
transferases themselves may actually "chaperone" their products to the endoplasmic reticulum 
(120). 
For the vast majority of mammalian proteins, the functional significance of these 
processing steps is not fully known. However, transgenic mice deficient in the CaaX protease 
usually die in late gestation or very soon post-partum (66). Fibroblasts from these mice 
demonstrate that the presence of this enzyme is necessary for proper association of Ras with 
the plasma membrane. Thus, the processing of the C-termini of newly prenylated proteins may 
play a very important role in the localization/biological activity of this class of lipid-modiHed 
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protein. A more comprehensive discussion of the biological significance of protein prenylation 
will follow in the next section. 
Because the thioether linkage between isoprenoid and cysteine residue is not labile, 
cells must possess a mechanism to dispose of the prenylcysteine that accumulates after the 
natural degradation of prenylated proteins. Famesyl cysteine has been shown to interact with 
the P-glycoprotein (Pgp) transporter (142, 143), and ATP-dependent export via Pgp may be a 
possible means of prenylcysteine clearance for cells expressing the transporter. However, 
most cells also express an enzyme capable of speciHcally removing isoprenoids from cysteine 
amino acids. This enzyme, prenylcysteine lyase, is likely to be the final processing step in the 
life cycle for the majority of an animal's prenylated proteins (121,144). 
CONSEQUENCES OF PROTEIN PRENYLATION 
When discussing the ultimate biological role covalently attached isoprenoids play in 
protein function, many researchers commonly assume (quite erroneously) that prenylation acts 
simply as a tether for membrane binding. However, up to one half of the total cellular 
prenylated protein is cytosolic (34); obviously, prenylation confers other properties to proteins 
in addition to membrane association. This section will therefore focus on the known effects 
prenylation has on protein localization, trafficking, and function by utilizing examples in which 
prenylation performs different functions depending on the protein to which the isoprenoid is 
attached. 
The most studied family of prenylated proteins is that of the Ras family (80). This 
group of low molecular weight GTPases functions as signal transduction conduits by 
coordinating signaling events from numerous growth factor pathways to a constantly growing 
list of downstream effectors (for a recent review of Ras signaling, see (125)). Ras proteins 
toggle between GDP-bound inactive, and GTP-bound active, states normally. However, 
transforming mutations can arise which lock Ras in its active GTP-bound state, thus activating 
downstream effectors even in the absence of upstream signal. Accordingly, Ras proteins 
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possess tremendous oncogenic potential; 30% of all human tumors harbor an activated Ras 
allele (7). Therefore, a great deal of effort has gone into understanding Ras biology in an 
attempt to design specific inhibitors that can block Ras signaling in human cancers. 
There are 4 major cellular forms of Ras: H-, N-, and K- (two alternatively spliced 
forms termed K4A and K4B). They are highly identical at the amino acid level, with especially 
high sequence conservation in their N-terminal effector binding regions. All possess CaaX 
motifs that signal for famesylation, and all but the K4B form are additionally palmitoylated on 
C-terminal cysteine residues (48). Instead of additional lipidation, K4B possesses a polybasic 
region in its C-terminus; the presence of a 'second signal' of palmitate or basic residues, in 
conjunction with the famesyl group, is necessary for sustained plasma membrane interaction of 
all Ras proteins. Stable membrane association is required for Ras activity, as mutants of Ras 
that cannot interact with membranes are non-transforming (130). 
The initial membrane binding event for Ras proteins is believed to be facilitated by the 
famesyl group, as mutants lacking isoprenoid are incapable of membrane association and 
transformation (55, 62). This discovery led to the search for compounds that could prevent 
Ras famesylation, and subsequently, its membrane association and oncogenic potential. To 
this end, potent, selective inhibitors of FTase have been developed; a discussion of their 
cellular effects will be presented later. 
Studies demonstrating the importance of famesyl in Ras membrane association have 
prompted questions regarding the mechanism of isoprenoid-mediated membrane association. 
Peptide studies clearly show that isoprenoids are capable of relatively weak hydrophobic 
interactions with membrane lipids, but require the presence of basic amino acids or secondary 
lipid modifications to achieve stable membrane interaction (76, 109, 113). Due to the weak 
interaction with lipids, some researchers have hypothesized that perhaps the isoprenoid on Ras 
can mediate protein-protein interactions with a putative 'Ras receptor' at the plasma membrane 
(114). However, the famesyl group is not required for Ras activity if the protein is artificially 
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targeted to the plasma membrane through the use of an alternate membrane anchor (11,14) or 
alternative lipids on the CaaX cysteine (6, 32). These studies suggest that plasma membrane 
association alone is sufficient for Ras activity. However, other work has shown the isoprenoid 
of Ras to play an important role in mediating events other than membrane association. 
In addition to initiating plasma membrane interaction, the famesyl group on Ras has 
been shown to participate in a number of other cellular events. Activation of Raf kinase, and 
other effector proteins, by Ras may be mediated in part by famesyl interaction with these 
proteins (84, 106). The C-terminus of Ras also plays a role in the trafficking and targeting of 
processed (proteolyzed and carboxymethylated) Ras from the endoplasmic reticulum to the 
plasma membrane (23, 131). Additionally, once at the plasma membrane, the combination of 
palmitates and isoprenoid on H-, N-, and K4A Ras may control the interaction of these 
proteins with specialized signaling subdomains of the plasma membrane such as detergent-
resistant membranes (DRMs) orcaveolae (33, 46, 82, 85, 86,92, 107). 
Although the role of prenylation in Ras biology has received a tremendous amount of 
attention, the physiological consequences of prenoid addition to a number of other proteins has 
also been investigated. Famesyl modification of the nuclear protein lamin A has proven to be 
an interesting example where prenylation does NOT confer plasma membrane localization. 
Instead, prenylation of lamin A is required for proper assembly into the nuclear lamina (S3). 
However, it is not the prenylated form of lamin A that is integrated into the nuclear envelope. 
Lamin A is substrate for a nuclear-localized preiamin A endoprotease that specifically 
recognizes the prenylated form of lamin A (preiamin A) and cleaves its Hnal 18 amino acids to 
generate mature lamin A (64,65). It is this form of the protein that is integrated into the lamina 
(81). Recent work has shown that the isoprenoid of prenylated, but not proteolyzed, preiamin 
A is also required for interaction with a newly discovered nuclear protein termed Narf (8). 
Therefore, in addition to directing plasma membrane localization, prenylation can also direct the 
10 
localization of proteins to various cellular locations (i.e. nuclear lamina) via isoprenoid-
mediated protein-protein interactions (i.e. recognition by prelamin A endoprotease). 
In addition to merely directing a protein's localization, work in the Held of G-protein 
coupled receptors (GPCR) and G-protein signaling has shown that isoprenoid addition can also 
directly influence the specificity and efficiency of signal transduction events. The prostacyclin 
receptor is the first GPCR shown to be prenylated (50). Preventing famesylation of this 
receptor decreases adenylate cyclase activation in response to ligand without influencing the 
ability to bind ligand. This suggests that the presence of famesyl on the C-terminus of this 
receptor is necessary for efficient activation of Gas. The type of isoprenoid attached to certain 
Gy subunits has also been shown to influence their ability to interact both with their receptors 
and also downstream effectors. For the yl subunit, famesyl is more efficient at promoting 
interaction with the rhodopsin receptor than is geranylgeranyi (68). Conversely, coupling of 
GPy subunits to the A1 adenosine receptor is favored by geranylgeranylation rather than 
famesylation of y subunits (134). The ability to activate the downstream effector 
phospholipase C-P has also been shown to be affected by the type of isoprenoid attached to the 
Gy subunit (88). Thus, prenylation not only can promote protein-protein interactions but may 
also be able to modulate the specificity and strengths of those interactions as well. 
Therefore, as our knowledge of the identities of prenylated proteins expands, so will 
the list of known functions isoprenoids play in protein activity. This information will be 
extremely important in the analysis of the effects of preventing cellular protein prenylation in 
treating human disease. The use and effects of prenyl transferase inhibitors will be discussed 
next. 
USE OF PRENYL TRANSFERASE INHIBITORS IN THE TREATMENT OF DISEASE 
As mentioned earlier, preventing prenylation of oncogenic proteins such as Ras holds 
the promise as a new area of cancer chemotherapy (for reviews on prenyl transferase 
inhibitors, see (13, 69, 93)). However, prenylated proteins play roles in many other human 
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diseases. Many non-cancerous pathologies that result from hypertrophic cellular growth may 
be responsive to prenyl Uransferase inhibitors. In fact, blocking cellular prenylation can reduce 
the progression of atherosclerosis (35), promote smooth muscle cell apoptosis (115) which 
may help in the treatment of hypertension and other vascular diseases, and can slow the growth 
of hypertrophic mesangial cells, which are associated with many renal disorders (9). In 
addition to the ever-growing list of naturally arising human disorders, prenylated proteins also 
may contribute the to the pathologies associated with viral (43,94) or microbial infection (49, 
136). Thus, the use of inhibitors of prenylation to treat disease may extend far beyond the 
scope of cancer biology. 
Competitive inhibitors of FTase or GGTase I can be grouped into two classes: 
compounds that prevent isoprenoid binding and compounds that block CaaX recognition. 
Although competitive inhibitors of isoprenoid binding exist (126, 133), nearly all of the 
inhibitors of FTase and GGTase I that are cunently being developed are designed to prevent 
protein substrate recognition. Through rational drug design based on the structure of the CaaX 
motif, and screening of drug libraries, numerous compounds have been identified that are 
potent and selective inhibitors of the prenyl transferases. Because of the interest in selectively 
preventing Ras famesylation, interest in the creation and discovery of FTase inhibitors (FTIs) 
has far outweighed that for GGTase I inhibitors (GGTIs). Therefore, although GGTIs have 
been shown to possess anti-tumor therapeutic potential (2, 118), the focus of this section will 
be on inhibitors of famesyl transferase. 
Because peptides as short as 4 amino acids can act as competitive inhibitors of FTase 
(102), rational drug design of small organic compounds modeled after the CaaX motif has 
yielded a number of promising inhibitors of FTase. Drug library screening has also yielded 
non-peptide inhibitors of protein binding to FTase. All of these drugs show great in vitro 
inhibition of FTase, with IC50 values in the low nanomolar range (10,24,58,70). In addition 
to being excellent in vitro inhibitors of FTase, these compounds are also biologically active 
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with respect to regressing Ras-mediated transformation both in cell culture (10,24,58,70) and 
in animal models (71). These drugs also show good activity in vivo against H-, N-, and K-
Ras tumor explants in nude mice (72). That these compounds appear efficacious in Ras-driven 
transformation models is quite interesting in light of recent work regarding their mode of 
action. 
Initial studies of FTI activity naturally centered on testing their in vivo ability to 
abrogate Ras signaling potential by preventing Ras prenylation. It was hypothesized that if 
prenylation of activated Ras proteins was prevented, then their ability to activate downstream 
effectors may be hindered, perhaps by the accumulation of cytosolic (and hence inactive) 
signaling complexes. Although early work showed that this did occur (56,75), the effective 
concentration of FTI that was necessary to inhibit K-Ras signaling was 100 times greater than 
that for H-Ras (57,75). This presents a signiHcant problem in the use of FTIs in the treatment 
of cancers, as the K-Ras oncogene is by far the most commonly activated form of Ras in 
human cancers (7). An explanation for this large difference in the effective concentrations of 
FTIs came with the discovery that the K- and N-Ras isoforms are capable of being alternatively 
C20-modified by GGTase I both in vitro (140) as well as in vivo in the presence of FTIs (105, 
129). Therefore, because of the potential for continued prenylation and membrane association 
of K-Ras in FTI-trealed cancer cells, the use of FTIs in the treatment of human tumors was 
questioned. 
Good news for researchers working on famesyl transferase inhibitors arrived with the 
knowledge that many tumor lines appear to be responsive to FTIs regardless of the activation 
status of their Ras proteins (112). Thus, it appears that prenylated proteins in addition to Ras 
may play a role in promoting cellular transformation. One non-Ras candidate prenyl protein 
that may be involved in mediating the cellular effects of FTIs is RhoB. RhoB is a C20-type 
CaoX-containing protein of the Ras superfamily that deviates from the CaaX hypothesis, as it 
naturally exists in famesylated and geranylgeranylated forms (1). RhoB is a substrate for both 
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FTase and GGTase I in vitro, and is exclusively geranylgeranylated in cells treated with FTIs 
(74). The C20-modified form has been hypothesized to promote the growth-inhibiting effects 
of FTIs, as co-expression of a C20-specific mutant of RhoB with activated Ras mimics the 
phenotype of FTI-treatment of cells expressing activated Ras (31). Thus the overall 
mechanism behind FTI activity may be the result of a decrement in Ras protein prenylation with 
accompanied loss or alternative prenylation of other CaaX proteins. However, continued work 
in this field is required before a complete understanding of FTI activity is reached. 
NOVEL ASPECTS OF CELLULAR PRENYLATION 
Although FTIs are in clinical trials for use in human cancers (93), the aforementioned 
studies clearly illustrate that prenyl transferases and their substrates (such as K-Ras and RhoB) 
do not always follow the CaaX hypothesis in vivo. Thus, more information is needed 
regarding the in vivo specificity and fidelity of prenyl transferases, as new classes of FTIs and 
GGTIs are being developed and used to prevent cellular prenylation. 
Presently, very little data exists to suggest that the enzymatic activity of prenyl 
transferases can be regulated. There are some reports that FTase activity may be influenced by 
insulin (44,45), but the effects seen in these reports appear minimal at best. The a subunit of 
FTase and GGTase I has been shown to associate with, and become phosphorylated by, the 
TGF-P receptor (63, 122, 128). However, the functional significance of this association and 
phosphorylation remains unknown. 
As mentioned with K- and N-Ras and RhoB, some CaaX proteins can be modified by 
the "wrong" prenyl transferase (i.e. the transferase NOT dictated by the CaaX motif). This 
phenomenon, termed cross-prenylation, demonstrates that N-terminal, non-CaaX regions of 
substrate proteins can have an effect on which type of prenyl transferase will modify the C-
terminus. This effect of N-terminal substrate protein elements on the fidelity of CaaX 
prenylation was also shown in a study using chimeric Gysubunits (60). Proteins possessing a 
C15-^pe CaaX motif could be cross-prenylated by GGTase I, but this cross-recognition could 
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be modulated based on the identity of N-terminal sequences. Clearly, prenyl transferases are 
influenced by substrate structures in addition to those encoded by the CaaX motif. 
In addition to cross-prenylation, limited examples of incomplete prenylation also exist. 
Primary cardiac myocytes (41) and 3T3-L1 adipocytes (44,45) possess considerable levels of 
non-prenylated, cytoplasmic Ras. This is quite unusual, because as mentioned previously, 
virtually all CaaJf-containing proteins, including Ras, are believed to be stoichiometrically 
prenylated (25, 78). One well known exception to this rule is that of the heterotrimeric Gai 
proteins. Gai subunits, terminating in 'CGLF CaaX motifs, should be targets for 
modification by GGTase I. However, these proteins are not prenylated in vivo, but instead 
remain free for ADP-ribosylation of the CaaX cysteine (59). Interestingly, if the CaaX of Gtti 
is mutated to resemble the FTase-type CaaX found on H-Ras, prenylation can occur. Thus, 
the lack of prenylation of Gai appears to be specific for GGTase I, and appears to be due in 
part to some non-CaaX structural element of Gai, the CGLF CaaX is at least partially 
prenylated when placed onto H-Ras (25). 
Thus, GGTase I's ability to cross-prenylate proteins such as K-Ras, N-Ras, and 
RhoB, along with its inability to recognize some of its own potential substrates (Gai), suggest 
that this prenyl transferase may have unique substrate requirements. Because it shares a 
subunit with FTase, and because the known binding site for CaaX substrates resides at the 
subunit interface, this poses a series of interesting questions as to how GGTase I recognizes 
and prenylates its substrates in vivo. We have attempted to address these issues using the 
Guanylate Binding Protein family as our model system. 
THF GIJANYLATE BINDING PROTEINS rGBPs) 
The Guanylate Binding Proteins, or GBPs, are a family of proteins that were 
discovered based on their interferon (IFN)-inducibility and were named due to their affinity for 
guanine nucleotides (19, 21). The cellular function(s) of this family of GTPases remains a 
mystery, although one report exists showing antiviral activity for a human GBP (3). Although 
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the role of these proteins in IFN-treated cells is unclear, this family of proteins has been shown 
to be a potentially useful marker for interferon activity in IFN-treated patients (20). 
Additionally, the gene promoters for human and murine GBPs have been instrumental in 
deciphering the signal transduction pathways associated with interferon-mediated transcription 
(12, 77, 91). Therefore, although the physiological function of GBPs remains unclear, this 
family of proteins has already contributed greatly to the field of interferon research. And as we 
will see, GBPs are now being shown to be useful models for the study of GTPases as well as 
novel aspects of protein prenylation. 
Presently, 8 members of the GBP family (2 human, 4 mouse, 1 rat, and 1 chicken) 
have been cloned (5, 22, 47, 110, 124, 132). All are roughly 600 amino acids (-65 kD) in 
length and possess nonstandard GTP-binding motifs. Although they show great specificity for 
binding to guanine nucleotides (22, 47), GBPs lack the canonical third element of the GTP-
binding motif that confers specificity for guanine (28). Based on their unusual GTP-binding 
domains, some researchers have speculated that GBPs belong to a new class of G-proteins that 
include members from diverse species such as arabidopsis and yeast (127). 
In addition to their unusual GTP-binding domains, all of the GBPs so far tested have 
the equally unusual ability to hydrolyze GTP to both GDP and GMP. GMP constitutes only 
10-15 % of the final hydrolysis product for human GBP-2 and chicken GBP (90, 110); 
however, it is the predominant product of GTP hydrolysis (85%) for human GBP-1 (111). If 
the GBPs interact with nucleotide-dependent effectors, this additional characteristic of the 
GBPs to produce GMP may have functional significance as it would allow for 3 separate 
nucleotide binding states. However, these individual states would most likely be transient if 
not stabilized by effector binding, as the rates of GTP hydrolysis are quite high. This appears 
to be due to very fast dissociation of hydrolysis products (99). 
Recent structural data on human GBP-1 has emerged showing this protein to adopt a 
highly peculiar structure as well (100). The N-terminal half of the molecule exists as a folded, 
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globular GTP-binding domain with some structural similarity to Ras. The C-terminal half is an 
elongated, rod-like domain composed entirely of a-helices. The authors of this work also 
showed that human GBP-1 exhibits nucleotide-dependent oligomerization and that human 
GBP-1 GTPase activity is protein concentration-dependent. This cooperative effect on GTPase 
activity, along with other biochemical and structural features, prompted the authors to suggest 
that GBPs are in fact members of the dynamin superfamily of GTPases. Further work is 
necessary to confirm or reject this hypothesis. 
Of the 8 cloned GBP family members, 6 possess CaaX motifs, with only human GBPl 
(hGBPl) having a CIS-type CaaX motif. Early investigation into the prenylation status of the 
GBPs showed that most behave as predicted by their CaaX motifs. Human GBP-1 has been 
shown to be famesylated in vitro (111) and in vivo (89). Ras p67 (123) and murine GBP-2 
(124) are also both prenylated in vivo. In vivo labeling experiments have shown the identity of 
isoprenoid attached to murine GBP-2 to be geranylgeranyl, also as predicted. However, an 
unexpected finding was obtained when we began studies into the prenylation status of murine 
GBP-1. 
Murine GBP-1 (mGBPl) was cloned independently from two different laboratories 
using interferon-treated embryo cells (22) or macrophages (132). This protein shares 
tremendous similarity to the other GBP family members, being 70% identical to human GBP-1 
at the amino acid level. Like the other GBPs, mGBPl shows exclusive specificity for binding 
guanine nucleotides, and it also possesses the same GGTase I-type CaaX motif (CTIL) found 
to be functional for rat p67 and murine GBP-2. However, unlike the other GBPs tested, our 
studies into the prenylation status of mGBPl, detailed in this thesis, show this protein to 
exhibit a startling deficiency in prenylation. This problem in prenylation appears to be an 
intrinsic property of mGBPl and demonstrates a new paradigm in prenylation whereby a 
protein with a functional CaaX motif fails to be stoichiometrically prenylated. A discussion of 
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the significance of this finding to the study of prenylated proteins, as well as the biological 
function of GBPs, follows the data chapters. 
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CHAPTER 2. MURINE GBPl: INCOMPLETE C20 
ISOPRENOID MODIFICATION 
OF AN IFN7-INDUCIBLE GTP-BINDING PROTEIN 
A paper submitted to Molecular Biology of the Cell 
John T. Stickney and Janice E. Buss 
Abstract 
Famesylation of Ras proteins is necessary for U'ansforming activity. Although faroesyl 
transferase inhibitors show promise as anti-cancer agents, prenylation of the most commonly 
mutated Ras isoform, K-Ras4B, is difficult to prevent because K-Ras4B can be alternatively 
modified with geranylgeranyl (C20). Little is known of the mechanisms that produce 
incomplete or inappropriate prenylation. Among non-Ras proteins with CaaX motifs, murine 
guanylate binding protein (mGBPI) was conspicuous for its unusually low incorporation of 
[^H]mevalonate. Possible problems in cellular isoprenoid metabolism or prenyl transferase 
activity were investigated, but none that caused this defect were identified, implying that the 
poor labeling actually represented incomplete prenylation of mGBPI itself. Mutagenesis 
indicated that the last 18 residues of mGBPI severely limited C20 incorporation, but 
surprisingly were compatible with famesyl (C15) modification. Features leading to expression 
of mutant GBPs with partial isoprenoid modification were identified. The results demonstrate 
that it is possible to alter a protein's prenylation state in a living cell so that graded effects of 
isoprenoid on function can be studied. The C20-selective impairment in prenylation also 
identifies mGBPI as an important model for study of substrate:GGTase I interactions. 
36 
Introduction 
Interest in prenylation has stemmed from the discovery that key proteins in multiple 
signal transduction cascades contain covalently attached isoprenoids (Casey, 1995). Perhaps 
the most notable examples are the Ras proteins. Mutated forms of Ras proteins are found in 
30% of all human tumors (Lowy and Willumsen, 1993). However, these mutant Ras proteins 
are not oncogenic if they cannot be prenylated (Lowy and Willumsen, 1993). Prevention of 
Ras prenylation thus holds promise as a new tactic for cancer chemotherapy (Cox and Der, 
1997). To this end, many prenylation inhibitors have been developed, several of which appear 
to be effective anti-cancer agents in animal studies and are undergoing clinical uials (Buss and 
Marsters, 1995; Gelb et al., 1999; Kohl et al., 1995; Liu et al., 1998). 
It is currently presumed that in order to be effective these drugs will need to prevent 
isoprenoid modification of oncogenic Ras entirely. However, forms of Ras which are 
incompletely modified have received little study (Gadbut et al., 1997; Goalstone and Draznin, 
1996), largely because of the assumption, based on direct physical studies, that prenyl proteins 
are fully and completely modified (Famsworth et al., 1990; Myung et al., 1999; Page et al., 
1990). It is still not known if all functions of oncogenic Ras require prenylation or if some 
effector pathways may remain active regardless of prenylation state. 
The signals which permit isoprenoid attachment are known in some detail. Either a 
famesyl (15 carbon) or geranylgeranyl (20 carbon) isoprenoid is attached through a thioether 
linkage to a cysteine residue at the C-terminus of the protein (Gelb et al., 1999; Seabra, 1998; 
Zhang and Casey, 1996). Enzymes that catalyze isoprenoid modification of proteins are 
grouped into two major classes: geranylgeranyl transferase U, which recognizes C-terminal X-
X-Cys-Cys, Cys-Cys-X-X, and Cys-X-Cys motifs, and CaaX motif prenyltransferases. CaaX 
motifs consist of a cysteine followed by two amino acids that frequently are aliphatic, then the 
final amino acid of the protein, X. The X residue is currently believed to be the major factor 
determining which of the two CaaX protein prenyl transferases will modify the CaaX cysteine 
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(Kinsella et al., 1991; Moores et al., 1991). Farnesyl transferase (FTase) modifies proteins 
with X residues such as Met, Ser, Ala, Gin or Asn. Geranylgeranyl Transferase I (GGTase I) 
preferentially modifles CaaX proteins with X residues of Leu or Phe. However, in cells treated 
with an FTase inhibitor, the K-Ras4B protein, whose CaaX motif (CVIM) is usually modified 
by FTase, can become C20 modiHed (James et al., 1996; Rowell et al., 1997; Sun et al., 1998; 
Zhang et al., 1997). This ability of GGTase I to modify particular FTase substrates is a 
difficult problem for design of drugs aimed at preventing Ras protein famesylation. Current 
inhibitors are designed to specifically inhibit FTase, and can do little to prevent K-Ras4B 
cross-prenylation by GGTase I. 
Despite the details identified regarding how isoprenoids are attached to proteins, little is 
known of the mechanisms that GGTase I or FTase use to exclude inappropriate proteins. 
FTase and GGTase I are heterodimers with a shared a, but distinct |3 subunits (Zhang and 
Casey, 1996). The ^ subunit binds the isoprenoid and is therefore responsible for the lipid 
specificity of each prenyl transferase. Recent crystallographic studies of FTase indicate that 
amino acids from both a and p subunits contribute to the site at which the CaaX motif of the 
protein substrate binds (Park et al., 1997; Strickland et al., 1998). This combination presents a 
further challenge for the design of CaaX -based inhibitors for FTase, which must bind FTase 
tightly, yet avoid interactions with the GGTase I enzyme in order to preserve the function of 
critical proteins that are C20 modified. 
Although Ras and other small GTPases are the most well known prenyl proteins, 
several other classes of CaaX-containing proteins exist. One such group is the family of 
Guanylate Binding Proteins (GBPs). GBPs are 65 kD proteins originally characterized based 
on their interferon-inducibility and ability to bind to guanine nucleotide affinity columns 
(Cheng et al., 1991; Wynn et al., 1991). Six of the 8 GBPs identified thus far possess CaaX 
motifs (Asundi et al., 1994; Cheng et al., 1991; Han et al., 1998; Schwemmle et al., 1996; 
Vestal et al., 1998; Wynn et al., 1991). Only one of the GBPs (human GBPl) has a CIS-type 
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CaaX (CTIS), and appears to be famesylated, as predicted (Nantais et al., 1996; Schwemmle 
and Staeheli, 1994). Other GBP family members have C20-type CaaX boxes. The CaaX 
sequence of mOBPl (CTIL) was predicted to be a good motif for isoprenoid attachment, based 
on the successful prenylation of 5 proteins with the same CTIL sequence (rat p67 GBP, murine 
GBP2, G74, murine mRpgr protein, and a plant calmodulin (Kalman et al., 1995; Rodriguez-
Concepcion et al., 1999; Vestal et al., 1996; Vestal et al„ 1998; Yan et al., 1998). However, 
despite having the hallmarks thought to be necessary, even favorable, for prenylation, 
isoprenoid attachment to mGBPl proved difflcult to detect. Detailed examination of possible 
reasons for the meager incorporation of [^H]mevalonate suggested that the defect was not the 
result of problems in cellular isoprenoid metabolism or prenyl transferase activity, but arose 
from mGBPl itself. 
Materials and methods 
Construction of DNAs: The 1.8 kb mGBPl coding region in pRC/RSV (Wynn et al., 1991) 
was amplified by PGR and cloned directionally into the pcDNAS vector (InVitrogen) using 
Not I and Xba I sites included on the PGR primers. Additional mutants were generated from 
this mGBPl gene using reverse primers that harbored the desired mutations. The GBPtRas 
chimera, Chim. was constructed using a primer complementary to the coding strand of the 
vector, with 24 mGBPl nucleotides plus 57 nucleotides corresponding to the Hnal 18 codons 
of K-Ras4B, plus stop codon and an Xba I site. Full length human GBPl was cloned into 
pcDNA3 after PGR amplification from the pHMG-SVpolyA vector (Cheng et al., 1991) using 
5' and 3' primers containing Bam HI or Not I restriction sequences respectively. Sequences 
of the mutated regions in all DNAs were veriHed before use in transfections. 
Cell Culmre. Transfection and IFN treatment: COS-1 cells were maintained in DMEM (Gibco) 
containing 10% calf serum (HyClone) supplemented with 2 mM L-glutamine, 1 mM 
sodium pyruvate, and penicillin/streptomycin. Purified plasmid DNA (1 -2 pg) was 
introduced into COS-1 cells using Lipofectamine (Gibco), and cells harvested 48 hours later. 
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RAW264.7 cells were maintained in RPMI media (Gibco) with similar additions but with 10% 
fetal bovine serum (HyClone). Endogenous mCBPl was induced by treatment of RAW264.7 
cells with IFNy (300 U/ml) and LPS (10 M-g/ml) for 20 hr. 
Metabolic labeling. Electrophoresis and Fluorographv: Transfected COS-1 cells were labeled 
overnight in medium containing 10% serum and 100 nCi/ml [3H]MVA (American 
Radiolabeled Chemicals, Inc.) in the presence of compactin (a generous gift from D. Graves) at 
SO |iM or as indicated in the Hgure legends. RAW264.7 cells were simuhaneously exposed to 
IFN/LPS and labeled with 100 pCi/ml [^HJMVA or 50 pCi/ml [^HJgeranylgeraniol 
(American Radiolabeled Chemicals, Inc.) in the presence of 50 compactin. Cells were 
lysed directly in electrophoresis sample buffer and samples separated by SDS-PAGE. Proteins 
were transferred by electroblotting onto PVDF membrane (NEN Life Science Products), the 
membrane sprayed with En^Hance (DuPont/NEN) and the [3H]-labeled proteins detected by 
fluorographic exposure. After fluorography, blots were stripped of fluorographic enhancer by 
rinsing with methanol and TTBS (Tris-buffered saline containing 0.5% Tween20). GBPs were 
then detected directly by immunoblotting the same membrane used for fluoragraphy. 
Tmrnunoblotting. Immunoprecipitation and Subcellular Fractionation: GBPs were detected 
using a rabbit polyclonal antibody to recombinant mGBPl (provided by D. Paulnock) with a 
biotinylated secondary antibody and alkaline phosphatase (Vector Labs). Endogenous H-Ras in 
COS-1 cells was detected similarly using the H-Ras-specific mouse monoclonal antibody 146-
03E4 (Quality Biotech, Camden, NJ). Immunoprecipitates were isolated by solubilizing cells 
as described (Vestal et al., 1998) and incubating the clarified supernatant with anti-GBP-coated 
Pansorbin (Calbiochem). Samples were washed and resuspended in electrophoresis sample 
buffer for analysis by SDS-PAGE. Membranes (PI00) were separated from cytosol (SI00) by 
centrifugation at 100,000 x g as described (Nantais et al., 1996). Proteins in both fractions 
were precipitated by the addition of four volumes of cold acetone, collected by centrifugation 
and resuspended in electrophoresis sample buffer. 
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Results 
FNmnr.ENOUS MGBPI IS POORLY LABELED BY flHIMVA IN IFN-TREATED RAW264.7 
CELLS 
Our early studies on the effects of IFNy/LPS on protein prenylation in murine bone 
marrow-derived macrophages had identified a 65 kilodalton prenyl protein (p65) that was 
strongly induced by this cytokine (Vestal et al., 1995). Incorporation of [3H]mevalonate into 
p65 was sensitive to the famesyl transferase inhibitor BZA-5B, implying that p65 was 
farnesylated. Clear potential candidates for p65 were the 65 kD IFN-inducible murine GBPs. 
However, both identiHed murine GBPs had C20-type CaaX motifs, and the mGBP2 protein 
appeared to be successfully C20 modified (Vestal et al., 1998). Therefore mGBPI was 
examined to learn if it would also be C2G modified or might instead be farnesylated. 
Unexpectedly, when the endogenous mGBPI protein was induced by treatment of RAW264.7 
cells with IFNy (Fig. 1), no prenyl protein was visible on the film at the correct molecular 
weight (Fig. 1). Just above the position of mGBPI two IFNy-inducible proteins were clearly 
[3H]MVA-labeled. These minor proteins were also recognized by the polyclonal anti-GBP 
serum. This indicated that RAW264.7 cells were capable of attaching isoprenoids to IFNy-
induced proteins, and suggested that some of these were potential GBP family members. 
Surprisingly, although the immunoblot showed that mGBPI was abundantly expressed, the 
amount of isoprenoid it contained appeared to be below our level of detection. 
Because [^HJMVA is converted into both [^HJfamesyl pyrophosphate and 
[^HJgeranylgeranyl pyrophosphate ([^HJGGPP), the possibility was tested that the poor 
labeling of mGBPI resulted from difficulties in transport of [^HIMVA or production of 
pHJGGPP in RAW264.7 cells. Examination of the other proteins present in the radiolabeled 
cell lysates did not encourage this theory, as many 21-28 kD small GTPases of the Rho and 
Rab families, most of which are geranylgeranylated (Reese and Maltese, 1991; Zhang and 
Casey, 1996), were successfully labeled (Fig. 1). To more directly examine geranylgeranyl 
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utilization, cells were incubated with [3H]geranylgeraniol ([^HJGGOH), an alcoholic 
isoprenoid that specifically labels C20-modified proteins (Crick et al., 1994). The several 
proteins between 30-80 kD that had been labeled with [^HJMVA, including the two ~66 kD 
IFNy-induced proteins, did not incorporate label from [^HJgeranylgeraniol. This suggested, as 
had been reported for other cell lines, that these larger proteins contained a CIS isoprenoid 
(James et al., 1994). The group of 21- 28 kD proteins was labeled effectively (Fig. 1), 
demonstrating that IFN-treated RAW264.7 cells metabolize [^HJGGOH to [^HJGGPP 
properly. However, once again, mGBPl labeling was below detectable levels. These results 
indicated that IFN treatment and the presence of mGBPl did not impair C20 isoprenoid 
incorporation into the appropriate proteins, and thus could not explain mGBP's poor labeling. 
MGBPl ALSO DISPLAYS POOR ISOPRKNOID INCORPORATION IN COS-1 CELLS 
Two other possible explanations for the poor labeling of mGBPl were that the poorly 
labeled, IFNy-induced protein was not actually mGBPl, or that the monocytic RAW264.7 
cells specifically had difficulty with mGBPl modification. These possibilities were tested by 
transiently expressing a molecular clone of authentic mGBPl in COS-1 cells so as to produce 
an amount of mGBPl similar to that attained naturally through IFNy treatment. An endogenous 
prenyl protein that migrated just above mGBPl (as well as the labeling of other prenyl proteins 
in the cell lysates) showed no differences in incorporation between mock transfected cells or 
cells expressing mGBPl (Fig. 2, upper panel). The positive control human GBPl protein 
(Nantais et al., 1996) was clearly labeled (arrowhead). However, isoprenoid incorporation into 
mGBPl was still below the level of detection. These results indicated that authentic mGBPl 
also encountered difflculties in labeling in another cell type. Thus the problem in labeling 
mGBPl was not restricted to monocytic or IFN-treated cells. 
To allow us to examine mGBPl more clearly, immunoprecipitation was used to isolate 
mGBPl from the endogenous prenyl protein of COS-1 cells. With this technique, 
incorporation of low amounts of label into mGBPl were detected (Fig. 2, lower panel). 
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Using immunoprecipitation to isolate larger amounts of mGBPl from RAW264.7 cells also 
revealed [3H]MVA incorporation in IFNy-induced mGBPl after long film exposure times (data 
not shown). This ability to detect mGBPl [3H]MVA incorporation in an immunoprecipitate did 
not derive from a more favored interaction of the GBP antiserum with prenylated forms of the 
protein, as the serum could capture uniform amounts of proteins from lysates even when the 
proteins showed up to 8-fold differences in labeling (see below). Reciprocally, the poor 
labeling of mGBPl seen directly in cell lysates (Fig. 1) also indicated that immunoprecipitates 
had not selectively lost a prenylated form of mGBPl. The antiserum thus could recognize 
equally both prenylated and non-prenylated forms of mGBPl. Therefore neither native, 
cytokine-induced, nor artifically expressed mGBPl were totally devoid of isoprenoid, but each 
appeared to contain so little lipid that the small amounts present were difHcult to detect unless 
the protein was concentrated and purified by immunoprecipitation. 
Finally, to determine if the problem with mGBPl labeling might be kinetic, from a 
slow equilibration of C20 pools or inefficient modiHcation by prenyl transferase, the amount of 
compactin utilized to inhibit cellular HMG-CoA reductase was decreased (see for example. 
Fig. 4, upper) to avoid unintentional depletion of C20 isoprenoids (Rilling et al., 1993), and 
extended labeling periods (up to 52 h, data not shown) were used. Both approaches failed to 
improve mGBPl incorporation. These data indicated that mGBPl underwent neither rapid but 
short-lived, nor slow but eventual prenylation, but was, at all times, poorly labeled. 
POOR LABELING OF MGBPl IS NOT DUE TO REMOVAL OF A PRENYLATED C-TERMINUS 
All of the above experiments indicated that, despite the expectation that the mGBPl 
CaaX motif should make the protein a good target, the difficulties underlying mGBPl's poor 
labeling did not involve isoprenoid metabolism or changes in prenyl transferase activity. 
Therefore reasons for limited incorporation that might arise from special properties of the 
protein itself were considered. An initial hypothesis was that mGBPl processing might 
resemble that of prelamin A. The prelamin A protein undergoes famesylation, but subsequently 
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loses the isoprenoid when the C-terminal 18 amino acids are removed (Kilic et al., 1997). It 
was judged that if a C-terminal domain of similar size were removed from mGBPl the change 
in length should be detectable, since the 589 amino acid mGBPl and 592 amino acid huGBPl 
proteins can be distinguished on our gel system (see Fig. 2). When compactin was used to 
limit isoprenoid synthesis and force accumulation of precursors of prenylated proteins, the 
endogenous H-Ras protein in the COS-1 cells collected in its unprocessed form, but the 
mobility of the transfected mGBPl protein did not change (Fig. 3). The 2 forms of mGBPl 
with slightly different mobilities also persisted after exposure to compactin and both 
incorporated [^H]isoprenoid (see Figs. 4 and 5) al the same low levels, suggesting that neither 
protein was a non-prenylated precursor of the other. Presumably some other modiflcation, or 
internal initiation of translation, generates these two forms. Thus, compactin u-eatment failed to 
cause accumulation of any specific precursor form of mGBPl and also failed to detect any 
potential isoprenoid modification that might have been difficult to observe by radiolabeling 
techniques. 
MGBP 1 WITH A C1 5-TYPE CAAX MOTIF IS MODIFIED WELL 
A second possibility was that the bulk of newly synthesized mGBPl might be 
concealed in some location that was inaccessible to GGTase I and (because they share an a 
subunit) also the FTase. This possibility was tested by creating a chimeric mGBPl (desipated 
Chim) with a signal for famesylation derived from K-Ras4B. [^HIMVA incorporation into this 
chimeric GBP:Ras protein showed a prominent increase above the native, wild type mGBPl 
(mGBPlwt) (Fig. 4), showing that FTase had no difficulty gaining access to the Chim 
protein. Therefore mGBPl was not sequestered. 
However, the loss of 18 residues and their replacement with a lysine-rich domain was a 
rather significant alteration of the mGBPl C-terminus. To address more precisely how well 
FTase could modify mGBPl, a less drastic mutant of mGBPl was made, with only the final 
"X" amino acid changed from leucine to serine. This mutant, designated CTIS, also 
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incorporated more label than mGBPlwt (Fig. 4). To judge if the increased labeling of the 
ens protein resulted simply from the change to FTase or might in addition result from an 
unintended improvement in presentation of the serine at the C-terminus to a prenyl (famesyl) 
transferase, an additional mutant was constructed. An alanine substitution in the CaaX "X" 
position (CTIA) was chosen to more closely mimic the leucine present in the natural CaaX 
motif. The mGBP-CTIA protein also showed improved labeling, to an extent similar to that of 
the mGBP-CTIS protein (data not shown). As this conservative change was unlikely to alter 
the C-terminal structure, it appeared that increased [3H]MVA incorporation resulted from the 
predicted change in the modifying prenyl transferase from GGTase I to FTase. 
The size of isoprenoid attached to these proteins was veriHed using [^HJGG-OH 
labeling. The mGBPl protein incorporated small amounts of [3H]GG-0H (Fig. 4, lower 
panel), providing evidence that what little isoprenoid was incorporated into mGBPl was of 
the expected, C20 type. The Chim and the CTIS proteins were not labeled by the [3H]-C20 
isoprenoid (Fig. 4, lower panel), indicating that the lipid detected on these constructs after 
[3H]MVA labeling was famesyl, as intended by their CaaX motifs. These results implied that 
mGBPl was acceptable as a substrate for FTase as long as it had the appropriate CaaX motif 
In addition, mGBPl was not the still-elusive p65 protein of bone marrow-derived 
macrophages. 
C-TERMINUS OF MGBPl INTERFERES WITH C20 MODINCATION 
At this point all the data pointed to the unexpected possibility that the problem with 
mGBPl prenylation was C20-specific. To determine if it was the C-terminus or a more distant 
part of mGBPl that caused this difHculty, a new, C20 version of Chim was constructed by 
remodeling the CIS-type K-Ras4B CVIM motif of Chim back to Cl'lL. This C20-Chim would 
thus be modified by [^H] C20 isoprenoid of the same specific activity as mGBPlwt. The only 
differences between mGBPlwt and C20-Chim were in the C-terminal 14 amino acids that 
mimicked those of K-Ras4B, adjacent to the C20-CaaX motif. As shown in Figure 5, 
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[3H]MVA labeling of C20-Chim was 2-3-fold higher than mGBPlwt. Therefore, mGBPl 
modification by C20 isoprenoid could be improved by inserting 14 K-Ras4B amino acids 
directly upstream of the CaaX motif. This result identiHed this region of the mGBPl C-
terminus as part of a structure that impaired C20 modification. 
Among these C-terminal residues of mGBPlwt were 3 consecutive prolines (Fig. 6). 
To determine if these prolines hindered C20-modification of mGBPl, a new mutant was 
constructed in which these residues were changed to arginines, the residues found in these 
positions in hGBPl. This "P to R" mutant was labeled -3 fold better than mGBPlwt, to a level 
similar to that of the more extensively altered C2Q-Chim. Therefore, among the C-terminal 
residues of mGBPlwt, these prolines were responsible for at least a portion of the difficulty in 
C20 modification. 
TsopRRNoro MODIFICATION OF MGBPI IS INCOMPLETE 
The consistent inequalities in labeling observed among these various GBPs suggested 
that these proteins might not be fully prenylated in mammalian cells (Fig. 6A). Direct 
measurement of mGBP's isoprenoid content by mass spectrometry was not practicable, as 
methods have not yet been developed for purification of sufficient amounts of mGBPl from 
mammalian cells (where the impairment occurs), especially given the small portion of native 
protein that appeared to be prenylated. Therefore, the fraction of each protein that contained 
isoprenoid was determined by dividing the amounts of [^H] isoprenoid incorporated into the 
various proteins by the amount of each protein that was expressed. To increase the accuracy of 
this analysis, both [^H] and protein measurements for each protein were drawn from a single 
immunoprecipitate blotted onto a single membrane. The membrane was first exposed to film 
for detection of [^H], then developed with GBP antiserum for quantification of protein. As an 
additional control, comparisons of immunoblots from total cell lysates and immunoprecipitates 
of cells expressing the various GBPs showed that all forms, including those well or poorly 
labeled, were immunoprecipitated with equal efficiency by the antibody. 
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These calculations indicated that the ClS-Chim protein contained the most 
[3H]isoprenoid (Fig. 6B). The [3H]:protein ratio of ClS-Chim was therefore set to 1 (as each 
protein molecule could contain no more than 1 isoprenoid, although it conceivably might 
contain less) and the ratios of the other GBP variants expressed relative to this value. This 
analysis quantised the previous visual results, and indicated that mGBPlwt contained only 13 
± 2% as much [^HJisoprenoid as ClS-Chim (Fig. 6B), thus implying that greater than 85% 
of mGBPl was not prenylated. Although the C20-Chim and "P to R" proteins were labeled 
more strongly than mGBPl wt, modification of these proteins also appeared to be incomplete 
(-30% of ClS-Chim). Thus all of the mGBP variants with C20-type CaaX motifs appeared to 
be poorly prenylated (Fig. 6B). Even the CIS-type CTIS protein was modified only -40% as 
well as the ClS-Chim. That the CTIS and ClS-Chim proteins had different levels of [3H]-C1S 
labeling further conHrmed that differences detected in incorporation of [^H] radioactivity 
reflected differences in amount of isoprenoid attached. Thus the level of isoprenoid 
modification of mGBPl that occurred within an intact cell could be manipulated over an 8-fold 
range by altering the last 18 residues. A more precise replacement of the 3 prolines with 
arginines could double the amount of C20-modined mGBPl, while simply switching to a CIS-
modified form could triple levels of prenylated mGBPl. 
Interestingly, hGBPl was also labeled less well than the ClS-Chim. These results 
suggested that modification of human GBPl, although efficient enough to allow detection, was 
also incomplete. Finally, a hGBPl with the C20 motif CTIL was labeled as poorly (12± S%) 
as mGBPl. The hGBP-C20 protein provided a second example where prenylation was far 
below stoichiometric amounts. The 3-fold difference in labeling of native hGBPl and hGBP-
CTIL illustrated again that in a pair of proteins in which all non-CaoX structures were identical, 
CIS and C20 modification could be di^erent. 
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PRF.NYT.ATTQN OF GBPS DOES NOT AFFECT MRMBRANE ASSOCIATION 
Because for some proteins isoprenoid modiHcation enhances membrane binding, 
mutant GBPs with wide variations in prenylation were examined to learn if this might lead to 
variable extents of membrane binding. The mGBPl wt, CTIS, "P to R", and huGBPl proteins 
were largely soluble (-70%, Fig. 7A), even though their extents of isoprenoid modification 
differed 3-fold, from 15% to 45%. Earlier work had already found 75% of (^HJMVA-labeled 
huGBPl in cytosolic fractions (Nantais et al., 1996), showing that the prenylated form of 
huGBPl was not restricted to membranes. Prenylation thus had little impact on membrane 
association of these GBPs. 
However, C15-Chim exhibited a distinct distribution, with significantly greater 
association with the PlOO fraction (-60%). When compactin was used to deplete the amount of 
famesyl available for prenylation of C15-Chim (Fig. 7B) the portion of C15-Chim present in 
the P fraction decreased. The compactin sensitivity of C15-Chim membrane interaction 
provided additional evidence, independent of radioactive labeling, that indicated the C15-Chim 
contained significant amounts of isoprenoid. 
Discussion 
mGBPl is the Hrst example of a protein in which a seemingly adequate CaaX motif 
almost completely escapes modification. The RhoA GTPase has been shown to exist naturally 
as a mixture of C15- and C20-modified forms (Adamson et al., 1992), but the stoichiometry of 
isoprenoid attachment has been presumed to be nearly complete. Rather than existing as a fiilly 
prenylated protein modified by one or the other isoprenoid, mGBPl is one of the few 
documented cases of incomplete prenylation. The ability of mGBPl to evade prenylation is 
particularly unusual because it applies selectively to modification of the protein with C20 
isoprenoid. Because the CllL CaaX sequence can be C20-modified in other proteins, it is clear 
that this negative control of isoprenoid modiHcation not only arises from regions of mGBPl 
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outside of its CaaX box, but must predominate over the otherwise acceptable CaaX motifs 
role. 
PRFNYI.ATION OF MGBPl IS INCOMPLETE 
Identifying mGBPl as a protein having a severe deficit in [^HJMVA labeling but with 
an outwardly acceptable CaaX motif was unexpected. Careful examination of cellular 
isoprenoid utilization determined that difficulty with production of [^HJisoprenoid or IFN-
induced alteration of prenyl transferase activity was not the cause of the poor incorporation. 
These results provide an important and necessary foundation for the precedent that difficulty in 
detecting incorporation of [3H] isoprenoid into a protein need not reflect experimental or 
cellular flaws, but may actually result from incomplete prenylation of the substrate protein. 
From comparison of labeling of mGBPl and the C15-Chim protein, we calculate that only 
15% of mGBPlwt molecules contain isoprenoid. This estimate is based on an assumption that 
the specific activity of the [^HJFPP and [^HJGGPP pools used to modify these proteins will be 
equal after >18 hours of labeling in minimal compactin. Even if C20 and CIS isoprenoids were 
to continue to harbor differences in specific activities, the much better labeling of mGBPl's 
C20-counterpart, C20-Chim. indicates that, at best, only one third of mGBPlwt is likely to be 
modified. Therefore the bulk of mGBPl, within an intact cell, genuinely appears to lack 
isoprenoid. Even this simple estimate gives mGBPl the distinction of being the most poorly 
prenylated protein identiHed thus far (Famsworth et al., 1990; Page et al., 1990). However, 
there are recent reports of non-famesylated Ras proteins in cholesterol-deprived cardiac cells 
(Gadbut et al., 1997) and insulin-starved 3T3-L1 adipocytes (Goalstone and Draznin, 1996). 
Our work with mGBPl and human GBPl now suggests that serious deficits in prenylation can 
occur in other proteins and cell types, and with either class of transferase. 
Native murine GBPl thus appears to exist persistently in the cell as a mixture of C20-
modified and (the more predominant) non-modified forms. However, the amount of 
isoprenoid-modiHed mGBPl could be increased, by up to 8-fold, by replacing mGBPl's 18 
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C-terminal residues. Furthermore, mutant proteins with varying degrees of C20 and CI5 
modiHcation could be produced by altering either more specific residues of the C-terminal 
domain or by changing the prenyl transferase responsible for modiHcation to FTase. Thus the 
extent of mGBP prenylation can be manipulated through relatively modest changes in the C-
terminal domain. Mutation of C-terminal residues of other proteins may similarly allow mixed 
populations of prenyl and non-modified proteins to be produced within a living cell and 
isoprenoid-sensitive functions studied. Experiments are underway to determine if replacing the 
C-terminus of K-Ras4B with that of mGBPl can be used to produce a mixture of lipidated and 
non-lipidated forms of an oncogenic Ras. This will allow study of responses that may be 
encountered if treatment with prenyl u-ansferase inhibitors is only partially effective. 
MECHANISM LIMITING PRENYLATION OF MGBPl 
The incomplete prenylation of mGBPl does not appear to result from Pre-Lamin A-like 
proteolysis or from sequestration of the protein from cellular prenyltransferases. Simply 
changing the CaaX motif of mGBPl to a form recognized by FTase significantly improved 
mGBPl modification. This indicates that the C-terminus of mGBPl is not likely to be 
obscured by another protein, as such masking would presumably impede interaction with either 
FTase or GGTase I. 
Occupation of the mGBPl CaaX cysteine by another modifying group remains a 
possibility, although we have not been able to detect incorporation of [^HJpalmitate into 
mGBPl (unpublished results). ADP-ribosylation of the mGBPl CaaX is a theoretical 
possibility, as pertussis toxin modifies the alpha subunits of heterotrimeric Gi and GQ proteins 
at a cysteine in the position analogous to the CaaX (West et al., 1985). However, in normal 
circumstances these alpha subunit cysteines are unmodified (Jones and Spiegel, 1990) and 
available to interact with heptahelical receptors (Blahos n et al., 1998; Yang et al., 1999). 
Additional information on the physiological fiinction of mGBPl will be needed to form a 
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clearer picture of whether the CaaX cysteine of mGBPl might undergo an alternative 
modiHcation. 
Notably, the mechanism that interferes with isoprenoid attachment to mGBPl appears 
to differ from that of the G alpha subunits. For the pertussis toxin-sensitive Gi alpha proteins, 
the glycine in the second position of the "pseudo-CaaX" sequence (CGLF) interferes with 
prenyl transferase interaction, making this sequence a very poor substrate (Jones and Spiegel, 
1990). In contrast, the CTIL CaaX motif of mGBPl has been shown to be a good substrate in 
other proteins (Kalman et al., 1995; Rodriguez-Concepcion et al., 1999; Vestal et al., 1998; 
Yan et al., 1998). Thus, the mechanism that negatively regulates mGBPl prenylation is 
sufficiently strong to limit prenylation of an acceptable CaaX motif. 
THF DEFECT IN MGBPI PRENYLATION IS SELECTIVE FOR C20 MODIFICATION 
The negative influence of C-terminal non-CaaX regions on mGBPl prenylation is 
intriguing because it appears to selectively impair the ability of GGTase I to modify the 
protein. This is most clearly seen with the CTIS mutant, which retains all residues of the wild-
type save for the final residue that confers FTase recognition, and which is modified 3 times as 
well as native mGBPl. The major impediment to GGTase I interaction appears to be in the C-
terminal region as replacement of 14 C-terminal residues (C20-Chim) or the somewhat unusual 
triplet of prolines (P to R) increases mGBPl's C20 modiHcation -3 fold. This C20-selective 
impairment in prenylation identifies mGBPl as an important model for study of 
substrate.GGTase I interactions. Using mGBPl as a platform, additional model structures that 
can produce this selective interference can be tested and help guide design of compounds to 
better prevent C20 modification of K-Ras4B. Including non-CaaX elements modeled on 
mGBPl may decrease a prenyl transferase inhibitor's affinity for GGTase I while retaining 
good FTase interaction. 
It will be important to determine if more distant residues outside the C-terminal region 
also contribute to the difHculQr in C20-modification. Work with chimeric G/s of heterotrimeric 
51 
G-proteins has previously suggested that GGTase I recognizes protein sequences outside the 
CaaX box (Kalman et al„ 1995). In vitro prenylation assays and further testing of deletion 
mutants of mGBPl in living cells will be necessary to clarify the location of these residues and 
whether they directly interfere with GGTase I interaction or bind another protein that 
selectively blocks enzyme access. 
An explanation of why mGBPl might evade prenylation is as yet unclear. Two 
somewhat divergent forms of murine GBPs (mag-2 and mGBP3) lack CaaX motifs, and 
therefore will not be prenylated (Han et al., 1998; Wynn et al., 1991). However, very little is 
known about the cellular function of any of the GBP proteins. A recent report indicates that 
human GBPl may, like the more well studied interferon-inducible MxA GTPase proteins, 
produce antiviral effects (Anderson et al., 1999). Whether mGBPl will show any natural 
variation in its prenylation or stay largely unmodified remains to be studied. The variety of 
mGBPl proteins constructed here, expecially the C15-Chim protein with its gain in prenylation 
and membrane association, may be useful for studies on GBP function. 
The exceptionally poor prenylation of mGBPl indicates that our understanding of the 
mechanisms which regulate interactions of prenyl transferases with their substrates is far from 
complete. Such information is particularly needed for the newly described prenyl transferases 
of protozoa (Yokoyama et al., 1998) or fungi (Omer and Gibbs, 1994), and for isoprenoid 
modified viral proteins such as Hepatitis Delta antigen (Glenn et al., 1998), where differences 
from mammalian enzymes and substrates may be exploited in the treatment of infectious 
diseases. 
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Figure Legends 
Figure 1. Incorporation of [^HJisoprenoid into mGBPl cannot be detected in EFNy treated 
RAW264.7 cells. RAW264.7 cells were labeled for 18 hr with either [^HIMVA (lanes I and 
2) or [3H]GG-0H (lanes 3 and 4) in the absence (lanes 1 and 3) or presence (lanes 2 and 4) of 
IFNy and LPS. Total cell lysates were displayed by SDS-PAGE and mGBPl detected by 
immunoblotting (Blot). Film is the fluorogram from the immunoblot shown, after 14 days 
exposure. With either labeled precursor, no radiolabeled band of the correct size for the 
induced mGBPl protein (dotted line) was detected after IFNy/LPS. However, two new 
[3H]MVA-labeled proteins (solid line) of slightly slower mobility appeared after IFNy/LPS 
treatment. Positions of molecular weight markers are shown on the side. 
Figure 2. Poor incorporation of [^H]MVA occurs in authentic mOBPl expressed in COS-1 
cells. {Upper) COS-1 cells were labeled for 18.5 hr with pH]MVA in the presence of 25 pM 
compactin, starting at 30 hr. after transfection with no DNA (U), or DNAs for mGBPl (mG) 
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or huGBPl (hG). Cell lysates were resolved by SDS-PAGE and radiolabeled proteins detected 
by fluorographic exposure for 13 days. (Lower) After transfection and labeling as above, 
mGBPl was isolated by immunoprecipitation (IP) and separated by SDS-PAGE. Incorporation 
of radiolabel into mGBPl was detected after fluorographic exposure for 21 days. HC denotes 
the heavy chain of the anti-GBP antibody. 
Figure 3. Compactin treatment does not alter mGBPl mobility. COS-1 cells were 
transfected with DNA encoding mGBPl with compactin (50 pM) added to the media 5 hr after 
transfection and remaining until samples were prepared 42 hr post-transfection. Cell lysates 
were separated by SDS-PAGE and endogenous H-Ras or the transfected mGBPl detected by 
immunoblotting. Lane 1 is from cells transfected with empty vector; lanes 2 and 3 are from 
mGBPl-transfected cells treated either in the absence or presence of compactin. Asterisk (*) 
denotes unprocessed H-Ras; the arrowhead shows fiilly processed, famesylated H-Ras. 
Figure 4. [^HJMVA labeling improves in mGBPl proteins with CI5 type CaaX boxes. 
COS-1 cells were transfected with empty vector (V) or DNAs encoding wild type mGBPl 
(wt), huGBPl (hG), or mGBPl variants with C15-type CaaX motifs (CTIS and Chim). Cells 
were labeled with either 1(X) |iCi/ml [3H]MVA plus 10 pM compactin or 50 MCi/ml [3H]GG-
OH and no compactin, and immunoprecipitates (upper) or cell lysates (lower) prepared and 
analyzed by SDS-PAGE. Incorporation of radiolabel was detected by fluorographic exposure 
for 22 days (pHJMVA) or 6 1/2 months ([^HJGG-OH), then GBPs on the membranes were 
visualized by immunoblotting. 
Figure 5. The C-terminus of mGBPl selectively hinders C20 modification. COS-1 cells 
were transfected with vector DNA or DNAs for various GBPs, labeled with [^HJMVA, 
immunoprecipitates formed and separated by SDS-PAGE. After fluorographic exposure for 22 
days, GBPs present in the immunoprecipitates were visualized by immunoblotting. 
Figure 6. C-terminal residues of GBPs and [^H]MVA incorporation relative to C15-Chim. 
(A) C-terminal amino acids of various GBP constructs are aligned. Changes from wild type 
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mGBPl or hGBPl are indicated in Bold. (B) Using the fluorogram and immunoblot from the 
same membrane, [3H]MVA incorporation and protein amounts of each immunoprecipitated 
GBP were quantified by scanning and values of [^HlMVA-derived label corrected for 
variations in protein recovery. The amount of [^H] for each GBP was then expressed relative 
to C15-Chim. Values shown are averages of these relative amounts, ± S.E.M. The number of 
independent experiments is indicated by n. One-way analysis of variance indicated that all GBP 
proteins incorporated significantly greater amounts of [^H] than mGBPl (p< 0.05), with the 
exception of the C20-modified huGBP-CTIL (hG-C20), which was not significantly different 
than mGBPl. 
Figure 7. Membrane association of GBPs which differ in prenylation state. ( A )  COS-1 cells 
were transfected with DNAs for the indicated proteins and 48 hr later separated into cytosolic 
(S) and membrane (P) fractions. Samples were separated by SDS-PAGE and GBPs detected 
by immunoblotting. (B) COS-1 cells were transfected with DNAs encoding mGBPlwt or 
C15-Chim. Treatment with 50 compactin was started 5 hr later. After 48 hr, lysates were 
separated into cytosolic (S) and membrane (P) fractions, separated by SDS-PAGE, and GBPs 
detected by immunoblotting. 
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CHAPTER 3. INHIBITION OF C20 MODIFICATION OF 
MGBPl'S CAAX MOTIF IS MEDIATED BY MGBPl C- AND 
N-TERMINAL PROTEIN ELEMENTS 
A paper to be submined to the Journal of Biological Chemistry 
John T. Stickney and Janice E. Buss 
Abstract 
Covalent attachment of isoprenoid lipids occurs on cysteine residues of C-terminal CaaX 
motifs of proteins. The thioether linkage formed between the isoprenoid and cysteine 
sulfhydryl is extremely stable and essentially irreversible in vivo. Thus, for isoprenoid 
attachment to be regulated, this control must occur prior to lipid addition. At the moment, there 
is little evidence that the enzymatic activity of prenyl transferases can be modulated, suggesting 
that control of prenylation would have to involve protein substrate preference and/or 
accessibility. In our efforts to better characterize how substrates are recognized by FTase and 
GGTase I, murine Guanylate Binding Protein-1 (mCBPl) was identifled as a protein that was 
very poorly prenylated in intact cells. Our initial studies showed that impairment occurred in 
mutant proteins with CIS-type CaaX motifs but was especially severe for C20 modification of 
the native CaaX motif, and also implicated 18 amino acids within the C-terminal region as part 
of a structure of mOBPl that limited prenylation. However, in the present studies, the C-
terminal 18 amino acids of mOBPl were shown to function well when appended to the K-
Ras4B protein, while expression of deletion mutants in COSl cells showed that proteins 
retaining as little as only the 300 N-terminal amino acids of mOBPl remained poorly 
prenylated. These results implicated both the extreme C-terminal structure and the N-terminal 
GTP-binding region of mGBPl as contributors to a prenylation inhibitory domain. Additional 
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in vitro studies showed that mGBP's C20-specific defect in prenylation could be replicated in 
reticulocyte lysates, thus verifying that full-length mGBPl is intrinsically a poor substrate for 
GGTase I. These studies provide the first example of a protein in which the native structure 
negatively regulates prenylation. This regulation appears to function through (selectively) 
limiting access of the CaaX motif to GGTase I by a combination of C-terminal and N-terminal 
mGBPl structures. 
Introduction 
Isoprenoid modification of the Ras family of proteins is critical for their biological 
activity. These binary molecular switches function normally to coordinate signals from 
numerous growth factor and signal transduction cascades to downstream effector proteins (for 
review, see (1)). However, activating mutations occur quite frequently within Ras genes; in 
fact, 30% of all cancers harbor a constitutively active, oncogenic Ras allele (2). Importantly, 
both normal and oncogenic Ras molecules rely on isoprenoid-mediated plasma membrane 
association to perform their biological activities (3,4). Thus, preventing prenylation of Ras 
proteins holds promise as a new class of cancer chemotherapy. 
Proteins that possess a CaaX motif as their final four amino acids are often substrates for 
prenylation (for a review of prenylation see (5)). Isoprenoid linkage occurs through the 
formation of a thioether bond between the isoprenoid and the CaaX cysteine (C of CaaX). 
Two types of isoprenoids (consisting of IS or 20 carbons) are attached to prenyiated proteins. 
The fmal amino acid of the CaaX motif (X) is thought to be the major determinant for which 
isoprenoid will be used. If X is Leu or Phe, then the CaaX cysteine should be modified with 
the 20 carbon isoprenoid (geranylgeranyl) by geranylgeranyl transferase I (GGTase I). If the 
final amino acid is Met or Ser (as is found in Ras proteins) or Gin or Ala, then famesyl 
transferase (FTase) will attach the IS carbon isoprenoid famesyl. Of the total number of 
prenyiated proteins found in mammalian cells, only 20% are famesylated (6). Therefore, 
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blocking famesylation in vivo is hoped to provide inhibition of Ras activity while having low 
toxicity due to the small number of other prenylated cellular proteins that would be affected. 
To this end, many inhibitors of famesyl transferase have been developed, and most 
appear to be very specific inhibitors of this enzyme in vitro and in vivo (7-10). However, in 
vivo studies show that not all Ras isoforms are equally sensitive to the action of FTIs (11,12). 
In the presence of FTIs, both of the K-Ras isoforms (4A and 4B) as well as the N-Ras protein 
can be alternatively modified with the 20 carbon geranylgeranyl by GGTase I (12,13). This 
presents a significant problem in the use of FTIs in treating human tumors as the most 
commonly mutated forms of Ras in human cancers are K-Ras and N-Ras (14). 
There is currently only a poor understanding of the mechanisms through which GGTase I 
can recognize and prenylate inappropriate substrates such as K-Ras. In vitro studies using 
peptide substrates and in vivo work using chimeric Ras proteins have shown that GGTase I 
can modify certain CIS-type CaaX motifs that terminate in Met and that possess multiple basic 
amino acids (a polybasic domain) N-terminal to the CaaX motif (12,15). Additional work 
using chimeric heterotrimeric G-protein y subunits has suggested that GGTase I is also 
sensitive to more distal N-terminal regions of its substrates (16). All of these studies have 
focused on GGTase I's ability to recognize CIS-type CaaX substrates that can be successfully 
modified by FTase. Information regarding proteins that should be prenylated by GGTase I 
but aren't would be extremely helpful in designing inhibitors to prevent unwanted 
geranylgeranylation of substrates such as K-Ras in cancer cells. We have recently identiHed 
murine Guanylate Binding Protein 1 (mGBPl) as a protein in which geranylgeranylation of its 
CaaX in vivo is extremely poor, and suggested that this difficulty might arise from a GGTase-
specific defect in mGBPl's prenylation. 
The Guanylate Binding Proteins (GBPs) are a family of proteins that were discovered 
based on their interferon-inducibility and afHnity for guanine nucleotides (17,18). Little is 
known regarding the physiological function of the GBPs, but they are among the RNAs that 
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are most highly induced by interferon stimulation (17). Recently, the 3-dimensional structure 
of human GBPl was solved, and the authors of that report suggest that the GBPs may be 
distantly related to the dynamin family of GTPases (19). Other work suggests human GBPl 
may also exhibit antiviral activity (20). 
Six of the eight identified members of the GBP family possess CaaX motifs (21-24), and 
as such, should be targets for prenylation. Human GBPl, rat p67, and murine GBP2 all 
appear to be modified as predicted by their CaaX motifs (23-25). However, in our initial 
studies of the prenylation of murine GBPl, we discovered that unlike other GBP family 
members, mGBPl failed to be effectively prenylated in vivo, even though it had the same 
CaaX motif found to be suitable for prenylation of both rat p67 and murine GBP2 (Chapter 2). 
No anomalies in cellular metabolism or utilization of isoprenoids, or alterations in cellular 
protein prenylation, were found that could explain the observed absence of modification of 
mGBPl. Analysis of mGBPl mutants revealed that residues within the C-terminus played a 
role in limiting prenylation in vivo. Replacement of the fmal 18 amino acids of mGBPl with 
the final 18 from K-Ras4B improved [^HJMVA incorporation 8-fold in COS-1 cells. 
Additionally, a single point mutation in the Hnal amino acid of the protein (Leu to Ser) that 
changed the prenyl transferase specificity from GGTase I to FTase also greatly improved 
prenylation of mGBPl. These results suggested that the C-terminus of mGBPl played some 
role in preventing prenylation of the CaaX motif in vivo, and that the deficiency was more 
severe with regard to modification by GGTase I. 
In order to better understand the mechanism behind mGBPl's GGTase I-specific defect 
in prenylation, we have studied the prenylation of this protein in vitro. The work reported here 
demonstrates that the C20-specific defect in mGBPl prenylation seen in vivo extends to in 
vitro conditions as well. Although previous studies showed the C-terminus of mGBPl to play 
a role in limiting C20 modification, analysis of deletion mutants presented in this paper 
indicates that the mechanism inhibiting geranylgeranylation of the mGBPl CaaX also includes 
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contributions from the N-tenninal GTP-binding domain. This suggests the possibility that 
prenylation of mGBPl may be a GTP-regulated event in vivo. 
Materials and Methods 
Construction of DNAs: Hemagglutinin (HA) epitope-tagged K-Ras4B constructs were created 
by PCR amplification of the 0.6 kb coding region of human K-Ras4B followed by cloning into 
the eukaryotic expression vector pcDNA3 (Invitrogen). PCR primer pairs containing Bam I 
and Xho I sites for directional cloning were used to create constructs possessing an N-terminal 
HA epitope (protein sequence MYPYDVPDYA) and the indicated C-terminus. HA-tagged 
GBPs were created in a similar fashion except that Not I and Xho I were used for cloning and 
the original initiator methionines in the GBP proteins were replaced by Leu. For DEL290/571, 
mGBPlwt DNA was digested with Tai I to remove nucleotides 871-1713, leaving in-frame Tai 
I ends that were re-ligated to create the internal deletion. For bacterial expression, all 
constructs were subcloned in-frame (using the restriction sites listed above) from pcDNAS into 
the pPROEX prokaryotic vector system (GIBCO BRL) which introduces 6 histidine residues at 
the amino-terminus of the protein. Sequences of the mutated regions of DNA constructs in 
pcDNAB were verified before use in transfections or subcloning into bacterial expression 
vectors. 
Cell Culmre and Transfection: COS-1 cells were maintained in DMEM (Gibco) containing 10% 
calf serum (HyClone) supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, and 
penicillin/streptomycin. Purified plasmid DNA (1-2 ^g) was introduced into COS-1 cells 
using Lipofectamine (Gibco) according to the manufacturer's protocol, and cells harvested 48 
hours later. 
In Vivo r3H1MVA labeling and Immunoprecipitation: Transfected COS-1 cells were labeled 
overnight in medium containing 10% serum and [^HJMVA (American Radiolabeled Chemicals, 
Inc.) at 67 ^iCi/ml (for K-Ras4B proteins) or 200 nCi/ml (for HA-GBP deletions) in the 
presence of 10 pM compactin (a generous gift from D. Graves). Cells were either lysed 
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directly in electrophoresis sample buffer, or proteins immunoprecipitated, and samples 
separated by SDS-PAGE. Immunoprecipitates were isolated by solubilizing cells as described 
(24) and incubating the clarified supernatant with anti-GBP or anti-HA-coated Pansorbin 
(Calbiochem). Samples were washed and resuspended in electrophoresis sample buffer for 
analysis by SDS-PAGE. 
Production of Recombinant Proteins: 100 ml cultures of transformed bacteria were grown at 
'iTC in LB containing ampicillin (50 |ig/ml) to a density of OD600=0.6. IPTG was then added 
to 0.6 mM and cultures were grown an additional 4 hours then collected by centrifiigation and 
stored at -70°C. For lysis, pellets were thawed, resuspended in 1ml of storage buffer 
containing protease inhibitors (20 mM Tris, pH 7.7, 1 mM DTT, 3 mM MgCh, 1% aprotinin, 
1 mM Pefabloc, 1 pg/ml leupeptin, and 1 ^ pepstatin) and sonicated 4 times at 4W for 30 
seconds, with cooling on ice. Insoluble material was removed by centrifiigation at 25,000 rpm 
at 4°C and the supernatant containing the soluble proteins was stored in aliquots at -1Q°C. 
Protein concentration was estimated by comparison of Coomassie Blue staining of the soluble 
GBPs to that of BSA standards. 
In Vitro T^^SIMethionine and T^HIMVA labeling: For in vitro transcription and translation of 
HA-KRas4B or mGBPI constructs, pcDNA3 vectors containing these genes were transcribed 
and translated in vitro using TNT T7 Quick rabbit reticulocyte lysate (Promega) per the 
manufacturer's protocol. Protein synthesis was detected by adding 10 pCi Redivue L-[3^S] 
methionine (Amersham) to the assay. For [3H]MVA labeling of in vitro transcribed/translated 
proteins, or of recombinant His-tagged proteins, 35 nCi [^HIMVA per reaction was added to 
individual assay tubes and dried as described (26) before addition of the reticulocyte mix 
containing DNA or recombinant protein. Reactions were allowed to proceed for 2 hours at 
30°C and were stopped by the addition of an equal volume of 2X SDS-PAGE sample buffer 
and 3 min. of boiling. 
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Fliinrngraphv and Immunoblotting: After SDS-PAGE, radiolabeled proteins were transferred 
by electroblotting onto PVDF membrane (NEN Life Science Products), the membrane sprayed 
with En^Hance (DuPont/NEN), and [^H] or [35S]-labeled proteins detected by fluorographic 
exposure to film. After fluorography, blots were stripped of fluorographic enhancer by rinsing 
with methanol and TTBS (Tris-buffered saline containing 0.5% Tween20). Proteins were then 
detected directly by immunoblotting the same membrane used for fluorography. GBPs were 
detected using a rabbit polyclonal antibody to recombinant mGBPl (provided by D. Paulnock) 
with a biotinylated secondary antibody and alkaline phosphatase (Vector Labs). Proteins 
possessing the HA epitope were detected using the hemagglutinin (HA)-specific mouse 
monoclonal antibody HA. 11 (Covance/BAbCO) with a horseradish peroxidase-conjugated 
secondary antibody (Pierce) and enhanced chemiluminescence (Pierce). 
Scanning and Quantification of Bands: Fluorograms and immunoblots were scanned, and band 
intensities quantified using the ImageQuant (Molecular Dynamics) program. Stoichiometry of 
prenylation was determined as the ratio of ([^HJMVA incorporated):(protein amount). Protein 
levels were based on immunoblot analysis or [35S] incorporation (normalized for the number 
of methionines). Potential differences in the specific activity of the C20 and CIS isoprenoid 
pools in [3H]MVA labeling experiments were not considered. 
Subcellular fractionation and TX-114 Phase Separation: Membranes (PI00) were separated 
from cytosol (S100) by centrifugation at 100,000 x g as described (25). After centrifugation, 
the SI00 supernatant was removed to a separate tube and the PI00 pellet resuspended in a 
volume of buffer equal to the S100. For TX-114 extraction, Triton X-114 (Sigma) was added 
to all fractions and phase separation performed by warming at 37°C for 2 min. and 
cenuifiigation at room temperature for 2 min. as described (27). Proteins in all fractions were 
precipitated by the addition of four volumes of cold acetone, collected by centrifugation, then 
resuspended and boiled in electrophoresis sample buffer. 
74 
GMP agarose: GMP agarose affinity experiments were performed essentially as described 
(21). 30 pi aliquots of GMP agarose slurry (Sigma) were added to 1.5 ml microcentrifuge 
tubes and were equilibrated on ice for IS min. with 1 ml of binding buffer (20 mM Tris, pH 
7.2, 150 mM NaCI, 5 mM MgCh, 0.1% Triton X-100). The slurry was sedimented and 
supernatant buffer was aspirated. GBP-containing cell lysates were added to the agarose bed 
and the final volume brought to 100 pi. After 30 min. on ice, the agarose was again 
sedimented, then washed 3 times with ice-cold binding buffer. To release proteins bound to 
GMP agarose, 30pl of IX SDS-PAGE sample buffer was added, samples boiled 5 min., then 
spun 5 min. at 14K to pellet agarose. The entire sample was used for SDS-PAGE and 
immunoblot analysis. 
Results 
THF. SOURCE OF THE C20-SPECIFIC DEFECT IN PRENYLATION IS MGBPL ITSELF 
Our previous work (Chapter 2) showing poor incorporation of [3H]MVA into mGBPl 
provided the first clear example of incomplete modification of a CaaX protein within intact 
cells. It also suggested that the difficulty in prenylation of mGBPl was more pronounced for 
C20 modification by GGTase I. To develop a more detailed understanding of the 
mechanism(s) underlying this impairment of isoprenoid modification, in vitro studies of 
prenylation of mGBPl were undertaken. Rabbit reticulocyte lysate was employed as a source 
of enzyme for synthesis of radiolabeled isoprenoid diphosphates from [^Hlmevalonate and also 
as a source of prenyl transferases (FTase and GGTase I). To examine the specific activities of 
the famesyl and geranylgeranyl diphosphate generated from [^HIMVA, K-Ras4B proteins with 
C15 and C20-type CaaX motifs were expressed in the reticulocyte lysate. K-Ras proteins 
possessing either FTase (CVIM) or GGTase-specific (Cl'lL) CaaX motifs were labeled very 
well, and showed equivalent [^H]MVA incorporation (Fig. 2). Thus, the reticulocyte lysates 
contained ample amounts of both the FTase and GGTase I enzymes and also efficiently 
produced both prenyl phosphates. This indicated that the reticulocyte lysate system could be 
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used to detect differences in stoichiometry of prenylation of GBP mutants by observing 
differences in [^HJMVA labeling. 
mGBPlwt (C20-type CaaX [CTIL]) and an FTase-specific mutant (CTIS) were 
expressed in bacteria, lysates prepared by sonication, insoluble proteins removed, and soluble 
proteins used in the in vitro assay. The concentration of GBP substrate proteins in the clarified 
bacterial lysates was estimated by Coomassie Blue staining and the volume of each lysate used 
was adjusted to provide equivalent amounts of each protein in the assay (compare lanes 1 and 
3, lower panel. Fig. 1). 
Comparison of the in vitro prenylation of the two GBPs that had been expressed in 
bacteria showed that the mGBPlwt protein possessing a C20-type motif incorporated much 
less label from [^HjMVA than did its counterpart with a CIS-type CaaX (CTIS) (Fig. 1, top 
panel). Because the previous results with K-Ras had shown that the specific activities of 
[^HJFPP and [^HJGGPP pools used for protein prenylation in the reticulocyte lysate were 
similar, this difference in labeling appeared to result from a selective inability of the C-
terminus of mGBPl to be modified by GGTase 1. 
To test if the poorer labeling of mGBPlwt was the result of a difference in the amount of 
C20-type protein that was folded correctly, both protein preparations were compared for the 
amount of mGBP that could bind to GMP-coupled agarose. Both proteins bound the GMP 
agarose, and the proportion of the C20-version of mGBPl that bound was equivalent to that of 
the CIS-version (Fig. 1, lower panel). The association of these GBPs with GMP-agarose was 
shown to be appropriately guanine nucleotide specific, as binding could be competed by the 
addition of GTP, but not ATP (data not shown). Thus improper folding did not explain the 
poor prenylation of the mGBPl protein. Therefore, as had been seen in previous in vivo 
experiments, mGBPl appeared to be an inefHcient substrate for prenylation. Moreover, 
mGBPl displayed a C20-speciflc defect in prenylation under cell-free in vitro conditions as 
well as in intact cells. 
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THF r-TF.RMINUS OF MGBPI CAN BE FULI-Y PRRNYLATED WHEN ATTACHED TO K-RAS 
Earlier results in COS-1 cells had shown that mutations within the final 18 amino acids 
could significantly improve [^HJMVA incorporation into mGBPl (Chapter 2). Those previous 
in vivo results together with results gained in vitro (Fig. 1) suggested that either the C-terminus 
of mGBPl directly impeded interaction and modification by GGTase I, or that the C-terminal 
domain of mGBPl formed part of a larger structure that inhibited GGTase I interaction. To 
test if the C-terminus of mGBPl was itself sufHcient to impair GGTase I interaction, the final 
18 amino acids of K-Ras4B were replaced by those of mGBPl, and the labeling of this 
chimera tested in COS-1 cells (Fig. 2A, K-Ras:GBP). A second mutant of K-Ras4B was also 
made, in which the wild type CIS-type K-Ras4B CaaX (CVIM) was replaced with the C20-
type CTIL CaaX of mGBPl. This pair of proteins thus allowed direct comparison of 
prenylation of proteins with identical CaaX motifs that would be modified by GGTase I using 
C20 isoprenoid from a common cellular pool. All K-Ras proteins were constructed to possess 
an N-terminal hemagglutinin (HA) epitope tag to allow the proteins to be immunoprecipitated 
and quantified (by immunoblot analysis) using a single antibody. 
Fig. 2B shows the results of one experiment in which these variant K-Ras4B proteins 
were expressed in COS-1 cells and labeled with [^HIMVA. Both the CIS and C20 versions of 
K-Ras4B incorporated radioactivity very well. The K-Ras:GBP protein incorporated less label 
than the other K-Ras4B proteins, but immunoblots showed that the total amount of chimeric 
protein that was expressed was also lower (data not shown). When the incorporation of label 
was normalized for the amount of protein immunoprecipitated, all three K-Ras4B proteins 
showed similar levels of prenylation (Fig. 2B, bar graph). Notably, the C20-version (CTIL) 
of the K-Ras4B protein had the same labeling as the K-Ras:GBP chimera with the same C20-
type CTIL motif (bar graph, Fig. 2B). These results indicated that, when removed from the 
context of the entire mGBPl protein, the C-terminus of mGBPl was a good substrate for 
prenylation and was capable of being fully modified by GGTase I in vivo. 
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Similarly robust incorporation of label into the chimeric K-Ras:GBP protein was also 
observed when the K-Ras variants were transcribed, translated, and labeled in vitro with 
[3H]MVA in a rabbit reticulocyte lysate (Fig. 2C). Equivalent amounts of [^H] isoprenoid 
were incorporated into K-Ras:GBP and K-Ras-CTIL. This again suggested that the C-
terminus of mGBPl could function well as a substrate for prenylation when removed from the 
structure of the mOBFl protein. These results with the K-Ras:GBP chimera are quite different 
from those obtained previously with full-length mGBPl proteins expressed in COS-1 cells, in 
which the presence of the wild-type mGBPl C-terminus was associated with very poor 
labeling. Although mutations in this C-terminal domain could improve [^HjMVA 
incorporation into wild type mGBPl, from this new data it appears that the C-terminal domain 
of mGBPl does not by itself impair interaction with GGTase I, but instead is part of a larger 
structure that inhibits GGTase I prenylation. 
THF C-TERMINUS OF MGBPl IS POORLY EXPOSED 
The ease of prenylation of the C-terminal domain of mGBPl when placed onto K-Ras 
suggested that in the wild type mGBPl the CaaX motif might be hidden by structures within 
mGBP itself or concealed by a GBP-interacting protein. To test if the C-terminus of mGBPl 
was exposed to solvent or hidden, the Triton X-114 extractability of a series of K-Ras 
chimeras and mGBPl variants was compared. Proteins that possess a hydrophobic group 
such as an isoprenoid can partition into the detergent ("D") phase of TX-114 if the lipid is 
exposed sufficiently to allow partitioning into the detergent micelles (28). The mGBPl and K-
Ras proteins have no hydrophobic domains within their primary structure, and thus must both 
have an isoprenoid and display it on the protein surface in order for the protein to be extracted 
into the "D" phase. 
To allow comparisons of proteins from a single cell lysate, COS-1 cells were co-
transfected with GBP and K-Ras proteins that possessed C-termini with the same amino acid 
residues. Cells were then separated into cytosolic and membrane-containing subcellular 
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fractions, and proteins in these fractions further divided (based on their hydrophobic character) 
by extraction into a Triton X-114 detergent phase. As previously shown, the native, fully 
prenylated mature K-Ras4B protein was entirely membrane-bound, and all protein in the 
membrane fraction was extractable into a TX-114 detergent phase (Fig. 3, panel 3). Upon 
longer exposure of the immunoblot, small amounts of the precursor form of K-Ras4B could be 
detected in the soluble (SlOO) phase, and that non-prenylated protein remained in the aqueous 
("A") phase after TX-l 14 extraction (data not shown). In contrast, the K-Ras:GBP protein, 
which has the same final 18 amino acids as mGBPl, was significantly more soluble (Fig. 3, 
panel 1). This partially cytosolic distribution results from replacement of the C-terminal 
polybasic domain of K-Ras4B with non-basic residues, and has been observed previously 
(29). Importantly, the cytosolic form of K-Ras:GBP partitioned completely into the detergent 
phase, indicating that the cytosolic protein was fully prenylated and that the isoprenoid was 
available for extraction. In addition, the 50% of the K-Ras:GBP that was found in the PlOO 
fraction also partitioned into the detergent phase. This indicated that the GBP tail was 
compatible with membrane binding, in addition to being suitable for prenylation. These results 
showed that when the GBP tail was placed onto another protein and modified with isoprenoid, 
the lipid was accessible and capable of directing that protein into the TX-114 detergent phase. 
In contrast, native mGBPl with the same C-terminal domain was only 30% in the PlOO 
fraction (Fig. 3, panel 2), and, of more importance, none of the mGBPl in the PlOO fraction 
partitioned into the "D" phase. This suggested that for the small amount of protein that did 
contain C20 isoprenoid, the lipid was not exposed. 
To address if the isoprenoid on a more fully prenylated GBP would exist in a similarly 
concealed state the partitioning of mGBPl :Ras, a chimeric form of mGBPl in which the C-
terminal 18 amino acids were replaced with the final 18 from K-Ras4B, was examined. The 
mGBPl:Ras protein had previously been shown to be prenylated quite well, as it incorporated 
8-fold more [^H]MVA than native mGBPl in COS-1 cells (Chapter 2). As had also been seen 
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previously, the mGBPl:Ras protein was found predominantly in the membrane-containing 
PlOO fraction (panel 4). But, during TX-114 extraction, the mGBPlrRas protein partitioned 
entirely into the aqueous ("A") phase. Therefore, although the 18 K-Ras amino acids 
(including the multiple basic residues that have been implicated in membrane binding of K-
Ras4B) increased membrane binding of mCBPl :Ras, the isoprenoid that was attached to the 
final C-terminal residue was inaccessible to TX-114 detergent extraction. These detergent 
extraction studies indicated that the body of mOBPl, or proteins that associated with mOBPl, 
could obscure even a prenylated C-terminus. The data of both the in vitro assays and that from 
intact cells further suggested that the C-terminus of mCBPl, although competent for 
prenylation, was a poor substrate when present in the context of mOBPl. This suggested that 
even without isoprenoid, the C-terminus of native mOBPl might assume a conformation that at 
least partially concealed the CaaX motif and restricted its access to GGTase 1. 
RFMOVAL OF C-TERMINAL AND INTERNAL DOMAINS DOES NOT IMPROVE MGBPI 
PRFNYLATION IN VIVO 
To identify region(s) of mGBPI that might act in conjunction with the C-terminus to 
impair prenylation by GGTase I, a series of deletion mutants was constructed (Fig. 4A). 
These were designed to remove amino acid segments that might interact with the C-terminus to 
conceal the CaaX motif, or bind another protein that masked this region. Each of these 
truncated GBPs was engineered to retain the mGBPI wt CaaX motif (CI'IL) and to contain an 
N-terminal HA epitope tag. The first mutant, DEL290/571 (DEL), had an internal deletion 
from amino acid positions 290 to 571 that placed the final 18 amino acids of mGBPI in-frame 
with the first 290 amino acids of mGBPI. This protein was used to ascertain whether removal 
of residues between position 290 and 571 would now allow the 18 amino acid mGBPI C-
terminus to be modified as efficiently as when it was present on the K-Ras:GBP protein. 
Mutant /^71 had the 14 amino acids directly N-terminal to the CaaX deleted. This mutant was 
constructed to learn if removal of these amino acids had the same positive effect on prenylation 
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as had been seen in the C20-Chim protein (Chapter 2) in which these amino acids had been 
replaced with the analogous sequence from K-Ras4B. Other mutants contained successive 100 
amino acid truncations of mGBPl with a CTIL CaaX motif appended to the residue number 
listed. A200 was chosen as the smallest potentially viable protein as this mutant included only 
the GTP-binding domain, which for Ras-family members is crucial for overall protein folding 
and stability (30). 
Expression and subcellular distribution of each truncated protein in COS-1 ceils was 
examined in order to determine the expression levels and stability of the proteins, and whether 
any gained the ability to bind to membranes (a crude indicator of possible improvements in 
prenylation). The AS71, ASOO, and A400 proteins were expressed at levels equivalent to 
mGBPlwt (Fig. 4B). DEL, and to a lesser degree A300, showed lower amounts of 
expression, suggesting that these deletions might cause some loss in protein stability. All of 
the mutants except A200 retained a mostly cytosolic distribution similar to that of mGBPlwt 
(Fig. 4B). The ^(X) protein was expressed very poorly, indicating that with nearly 4(X) amino 
acids removed, the remainder of the protein showed poor stability. The mechanism through 
which this small amount of protein became associated with the PKX) fraction was not further 
investigated. Thus for all but the smallest deletion mutant, these proteins showed no change in 
membrane binding or indication of increased prenyladon. 
To determine how well these constructs were prenylated in vivo, COS-i cells were 
transfected with the various GBP deletions and were labeled overnight with [^HIMVA. K-
Ras4B possessing the same C20-type CaaX motif as mGBPl (CTIL, Fig. 2A) served to 
establish the ratio of [^HIMVA incorporation/protein expression for a fiilly prenylated protein. 
mGBPlwt with the same HA epitope tag served as the baseline for poor prenylation (-10% of 
K-RasCTIL). If mGBPl possessed an N-terminal protein element that prevented prenylation, 
we predicted that its removal would result in a dramatic improvement in the MVA/protein ratio 
to a value similar to the fully prenylated K-RasCTIL protein. Unexpectedly, initial experiments 
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resulted in barely detectable labeling of any of the truncated GBP proteins (data not shown). 
Only after increasing the concentration of radiolabel 3-fold (2(X)nCi/ml) could the low level of 
MVA incorporation into these GBPs be readily observed (Fig. 5A). Comparison of [^HIMVA 
incorporation per amount of protein showed that none of the deletion mutants incorporated 
significantly more [^H] label from MVA than mGBPlwt (Fig. 5B). In fact, the A300 form, 
whose expression was roughly similar to the other mutants, showed a marked decrease in 
prenylation to barely detectable levels. Additionally, the DEL protein in which the 18 amino 
acid C-terminus of mGBPI was appended to position 290 was a very poor substrate for 
prenylation, even though the C-terminus had been shown earlier to be a suitable substrate for 
modification when placed onto K-Ras (Fig. 2B,C). This poor MVA incorporation into the 
truncated GBP proteins could not be explained by protein sequestration or insolubility, as the 
majority of the proteins were found to be cytosolic (Fig. 4B) and thus should have been 
available for modification by the soluble GGTase I enzyme. Therefore, although the C-
terminal 14 residues of mGBPI were shown previously to have a negative impact on 
isoprenoid modification of the CaaX motif, their removal, or the removal of up to nearly 300 
C-terminal amino acids, did not appear to alleviate the difHculty of mGBPI prenylation in vivo. 
These results make it clear that the regions of mGBPI that impede prenylation of the CaaX do 
not reside solely in the C-terminus, but also include the N-terminal third of mGBPI that 
encompasses the GTP-binding domain. 
PRRNYLATION OF MGBPI DELETION MlfTANTS IS NOT IMPROVED IN VLTRO 
To address whether the in vivo results obtained with the mutant GBP proteins would 
extend to cell-free conditions as well, we again employed the rabbit reticulocyte in vitro 
prenylation assay. Recombinant GBP deletion mutant proteins possessing the HA epitope 
were expressed in bacteria, and GBPs in the soluble fraction were added to the reticulocyte 
lysate in the presence of [3H]MVA. The results, similar to those that had been seen in vivo, 
showed that none of the GBP deletion mutants incorporated substantially more [^HIMVA than 
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mGBPlwt (Fig. 6). In fact, the relative levels of MVA incorporation closely mimicked those 
seen in COS-1 cells, with the A300 protein being an extremely poor target for 
geranylgeranylation. Even the A200 mutant, which could be stably produced in bacteria, 
remained largely unmodified. Control reactions showed that the K-Ras4B protein produced in 
bacteria was a much better substrate (- 6-fold, data not shown) for prenylation than the GBP 
deletion mutants, indicating that the reticulocyte lysate could prenylate good substrates easily. 
Thus, the lack of improvement in prenylation of these mutants observed in vivo was not due to 
their presence in a mammalian cell or to problems in access to GGTase I. Instead, the N-
terminus of mGBPl, including the GTP-binding domain, appeared to prevent prenylation of 
the C-terminal CaaX motif. 
Discussion 
The experimental results presented here have confirmed mGBPl's status as the only 
known protein possessing a largely non-prenylated CaaX motif. The mechanism underlying 
this deficiency in prenylation appears to be complex, consisting of contributions from both the 
extreme C-terminus and N-terminal GTP-binding domain. Thus, mGBPl provides a novel 
model for the study of cellular mechanisms governing in vivo selection of substrates by FTase 
and GGTase I. This identification of a new inhibitory domain contributes to the understanding 
of prenyl transferases and the continued development of improved inhibitors of these enzymes. 
THF C20-SPECIF1C DEFECT IN MGBPl PRENYLATIQN IS AN INTRINSIC PROPERTY OF ITS 
STRUCTURE 
Our previous in vivo results showed that the endogenous form of mGBPl authentically 
induced by IFN treatment of macrophages, and also forms transiently expressed in COS-1 
cells, exhibit a C20-specif1c defect in prenylation. Changing the transferase speciHcity at the 
CaaX motif from GGTase I to FTase (via a Leu to Ser CaaX substitution) resulted in a 4-fold 
increase in [^HJMVA incorporation (Chapter 2). Our current data shows that this C20-specific 
defect does not arise from in vivo problems in GGPP production, GGTase I activity, or 
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substraterenzyme inaccessibility, as limited in vitro C20-modification also occurs using rabbit 
reticulocyte lysate and recombinant mGBPlwt (Fig. 1). Therefore, the poor GGTase I-
associated prenylation of mGBPl is not due to its presence in the environment of a living cell, 
but instead reflects an intrinsic inability of the protein to be effectively modifled by GGTase 1. 
Studies using chimeric Gy subunits from heterotrimeric G proteins showed that N-
terminal regions of CaaX substrate proteins can play a large role in determining which prenyl 
transferase will recognize and prenylate the CaaX cysteine (16). However, in contrast to the 
work presented here, the chimeric Gy proteins in the aforementioned study continued to be 
recognized and prenylated by either FTase or GGTase I. Our work with mGBPl shows that 
non-CaaX regions of substrate proteins can selectively, and negatively, influence CaaX 
modification by impeding prenylation by one prenyl transferase over another. This finding is 
quite interesting in light of the fact that the CaaX substrate binding site of both FTase and 
GGTase I resides in a cleft between a and P subunits, of which the a subunit is common to 
both enzymes (5). Our work with mGBPl provides new information that improves our 
understanding of the mechanisms behind prenyl transferase substrate recognition. 
THF C-TERMINUS OF MGBPl IS A GOOD SUBSTRATE FOR PRENYLATION 
Earlier work by James et al showed that a polybasic domain within the C-terminal 18 
amino acids of K-Ras promoted cross-prenylation of the CaaX motif by GGTase 1(15). Our 
previous results implicated a similar 18 amino acid C-terminal region of mGBPl in blocking 
efficient prenylation by GGTase (Chapter 2). We therefore reasoned that amino acids within 
this region of mGBPl might play a key role in limiting GGTase I interaction. However, 
chimeric K-Ras proteins possessing the C-terminus of mGBPl were prenylated well, both in 
vivo in COS-1 cells and in vitro in a rabbit reticulocyte lysate (Fig. 2). Thus, in the case of 
mGBPl, the final 18 amino acids of mGBPl appear to require N-terminal parts of the native 
protein to hinder prenylation of the CaaX. 
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That the C-terminus of mGBPlwt appears to be poorly recognized by GGTase I may be 
due to the conformation of mCBPl itself or perhaps concealment of the C-terminal domain by 
a GBP partner protein. The poor TX-114 extractability (Fig. 3) of both prenylated 
(mGBPChim) and non-prenylated (mGBPlwt) forms of mGBPl suggests that the C-terminus 
of mGBPl is concealed from GGTase I, thus limiting its prenylation. 
THF N-TERMINUS OF MGBPI ACTS TO LIMIT CAAX PRENYLATION 
Because the final 18 amino acids of mGBPl were compatible with GGTase I 
modification, it appeared that other regions of mGBPl were required to produce the 
prenylation deficiency. Using a series of GBP deletion mutants, the N-terminal third of 
mGBPl, containing the GTP-binding domain, was identiHed as a region that impaired CaaX 
modification (Fig. 5). To our knowledge, this is the first case in which a nucleotide-binding 
domain has been shown to affect prenylation of a CaaX motif. For the Rab GTPases, protein 
prenylation by the Rab prenyltransferase (GGTase 11) is influenced by the Rab protein 
nucleotide state. This effect arises because, unlike CaaX prenyltransferases, GGTase n has a 
third subunit termed Rab Escort Protein (REP). REP preferentially associates with newly 
synthesized GDP-bound Rab proteins and presents them to the GGTase Q transferase 
machinery for prenylation (5). However, REPs are quite selective for GGTase n and Rab 
proteins, and are unlikely to provide the explanation for the lack of prenylation of mGBPl. 
However, it does remain a possibility that mGBPl associates with a partner protein(s) that 
could hinder access to the CaaX motif. 
SRI.F ASSOCIATIVE VS. PARTNER PROTEIN OCCLUSION MODELS FOR PRENYI ATTON 
Mimnm 
In an effort to construct models for how the N-terminus of mGBPl could be hindering 
access to its own CaaX motif, we have turned to the recently solved three-dimensional 
structure of human GBP-1 (hGBPl) (19) as a source of GBP structural information. mGBPl 
and hGBPl are 70% identical at the amino acid level, and secondary structure predictions for 
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mGBPl show close resemblance to the determined secondary structure of hOBPl 
(unpublished data). Thus, it is very likely that the overall folding of mGBPl mimics that of its 
human homologue. 
The N-terminal 300 amino acids of hGBPl (the GTP-binding domain) are folded into a 
globular domain loosely resembling that of Ras. The C-terminal half of the molecule is 
comprised entirely of a-helices and folds into what appears to be a very rigid, rod-like domain. 
This rod-like structure is composed of two three-helix bundles that extend away from the 
globular domain and a single -80 amino acid helix that is folded back, making contact with 
both the helix bundles and the GTP-binding domain. The long helix terminates with a turn and 
another short helix that is anti-parallel to the long helix. Although the extreme C-terminal 
region containing the CaaX is disordered, it is unlikely that the main part of the C-terminal 
domain of the protein exhibits much flexibility due to the apparent rigidity of the structure and 
number of intramolecular contacts between helices. 
Based on this structure, and other data suggesting that hGBPl can undergo GTP-
dependent oligomerization, the authors of the structural paper speculate that hGBPl is a 
member of the dynamin family of GTPases (19). Dynamins, as well as the Mx family of 
interferon GTPases, have been shown to exhibit the type of C-terminal molecular 
"backfolding" present in hGBPl and are also capable of oligomerization (31-34). Thus, if 
mGBPl were to behave similarly (i.e. oligomerize), then perhaps multimerization of mGBPl 
could bury the CaaX motif such that it would not be available for modification. 
At the present time, our additional preliminary data do not strongly support an 
oligomerization model for three main reasons. First, we do not observe a shift in SDS-PAGE 
mobility of mGBPl after chemical cross-linking COS-1 lysates containing mGBPl. Secondly, 
we have not seen any evidence of mGBPl self association using yeast two-hybrid analysis. 
Finally, and most tellingly, dynamin and Mx protein self-associations require the interaction of 
C- and N-terminal elements (31-34). Thus, it is difficult to envision how truncated GBP 
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proteins such as A300, which lack the entire C-terminus and are comprised of only the globular 
GTP-binding domain, could retain the ability to multimerize in a fashion similar to the dynamin 
or Mx proteins. 
Currently, our data favor a model in which a partner protein associates with the N-
terminal GTP-binding domain, and the nearby CaaX motif, of mGBPl and blocks access of 
the CaaX to GGTase I. This model is based loosely on the example from RhoGDI binding to 
the members of the Rho family of small GTPases. In this case, RhoGDI is a partner protein of 
the Rho/Rac/Cdc42 GTPases and makes contacts with both the GTP-binding domain and the 
prenylated C-terminus of the GTPase to extract the protein from the membrane to which its 
attached (35). The effect of GDI binding is to sequester the GTPase protein in the cytosol 
where it remains inactive until released from the GDI. Our model proposes that mGBPl has a 
similar binding partner that covers the CaaX motif until a signal for its release arrives, at which 
time the CaaX would be uncovered and available for prenylation. 
This model presents a testable hypothesis for further experimentation into the novel 
mechanism mGBPl uses to block its own prenylation. Future study of this protein should 
allow for both a better understanding of the cellular mechanisms governing substrate choices of 
prenyl transferases as well as new insight into the biology of the GBPs. 
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Figure Legends 
Figure 1. mGBPl displays a C20-specific defect in prenylaiion when labeled with [^HIMVA 
in vitro. {MVA) Bacterially produced His-tagged mGBPlwt and an FTase-specific point 
mutant (CTIS) were added in equal amounts to separate tubes containing rabbit reticulocyte 
lysate with 35 fiCi [3H]MVA and incubated at 30°C for 2 hours. Aliquots were displayed by 
SDS-PAGE, transferred to PVDF, and radiolabeled proteins detected by fluorography after 4 
days exposure to film. Protein amounts of GBPs in the bacterial lysates were adjusted so that 
equal amounts were used in the in vitro assay. Amounts were confirmed by intensity of bands 
after immunoblot analysis (lower panel, L). (Blot) Amounts of bacterial lysates identical to 
those used in the in vitro prenylation assay were loaded (L) onto GMP-agarose and after 
washing, the amount of protein remaining bound to the agarose (B) was released by the 
addition of SDS-PAGE sample bufler followed by boiling. 
Figure 2. The C-terminus of mGBPl can be fully modified when placed onto K-Ras4B. A) 
Alignment of the C-termini of HA-tagged K-Ras4B proteins with differences from wild type 
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residues shown in bold. B) COS-1 cells were transfected with the indicated constructs or 
empty vector (V) and labeled overnight with 67 pCi/ml [^HJMVA in the presence of 10 pM 
compactin. upper panel-MWK Proteins were immunoprecipitated using a monoclonal anti-HA 
antibody and labeled proteins visualized by fluorography as in Fig. 1 after 28 days exposure. 
lower panel-E\ot After fluorography, the membrane was stripped of enhancer and used for 
immunoblot detection using the anti-HA antibody. LC denotes the light chain of the antibody 
used for immunoprecipitation. Bar graph -Ratios of [3H]MVA incorporation per amount of 
protein present in the immunoblot were calculated and expressed relative to K-Ras4B 
possessing a wild type, CIS-type CaaX (wt). Number of experiments is indicated over 
columns and bars represent S.E.M. Q Plasmid constructs used in transfection experiments 
(B) were transcribed and translated in a rabbit reticulocyte lysate containing 35 fiCi [^H]MVA 
to detect prenylation or lOpCi [3^S]methionine to visualize protein levels. Radiolabeled 
proteins were visualized by fluorography after 4 days for M\'A or 12 hours for Bar graph 
- Ratios of [3H]MVA incorporation per amount of protein were calculated as in B) with error 
bars representing the range of values from two separate experiments. 
Figure 3. The exposure of the C-terminus of mGBPl differs greatly from that of K-Ras4B. 
mGBP and K-Ras4B proteins with equivalent C-termini (mGBPl or K-Ras4B) were co-
expressed in COS-1 cells and subjected to SlOO/PlOO fractionation followed by TX-114 phase 
separation. Calculated Fraction with Isoprenoid refers to the observed stoichiometry of 
prenylation as determined by MVA/protein ratios in COS-1. Comparisons of the ratio of 
[3H]MVA/protein for mGBPl wt and a CIS-specific chimeric mutant (mGBPl :Ras) in COS-1 
cells showed that mGBPl wt incorporates approximately 12% the amount of MVA label/protein 
as does mGBPl;Ras (Chapter 2). These values were used to assign a stoichiometry of 
prenylation of 12% for mGBPlwt assuming 100% prenylation for mGBPlrRas. 
Figure 4. Deletion mutants of mGBPl are stable and soluble when expressed in COS-1. A) 
Cartoon diagram of various mGBPl deletion mutants with the GTP-binding domain (G-
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domain) depicted by shading. B) COS-l cells expressing proteins described in A) were 
separated into SlOO and PlOO fractions as described above. After acetone precipitation, 
proteins were resuspended in 100 (il of IX SDS-PAGE sample buffer and 20 |il of each 
sample loaded per lane. After SDS-PAGE and transfer to PVDF, proteins were detected using 
an anti-HA antibody as described in Materials and Methods. Because of limited expression of 
DEL290/571 (Del) and A200, these proteins were visualized by longer exposure times during 
development of the ECL immunoblot (inset panel, bottom). 
Figure 5. Removal of the C-terminal half of mGBPl does not improve MVA incorporation in 
COS-1. A) COS-1 cells were transfected with K-Ras (arrow) or GBP proteins possessing N-
terminal HA epitope tags and labeled overnight in the presence of 200 pCi/ml [^HIMVA. 
Following immunoprecipitation, captured proteins were released from immunoconjugates by 
boiling in the presence of IX SDS-PAGE sample buffer. After SDS-PAGE, transfer to 
PVDF, and fluorographic exposure, proteins possessing the HA epitope were detected on the 
same membrane using immunoblot analysis as described above. B) The bar graph 
summarizes MVA:protein ratios of the various GBP mutants relative to mGBPl wt. Percent of 
mGBPlwt prenylation was set to 12% of stoichiometric prenylation (i.e. Ras) as in Fig. 3. 
Number of experiments is shown as N and error bars represent S.E.M. Due to the poor 
expression of A200, analysis of prenylation of this mutant was not possible. 
Figure 6. MVA incorporation into GBP deletion mutants is not improved in reticulocyte 
lysates. A) Recombinant GBP deletion mutant proteins, expressed in bacteria, were added to 
rabbit reticulocyte lysates and their MVA incorporation tested as in Fig. 1. Blot To quantify the 
amount of recombinant protein that was added to the reticulocyte lysate, representative amounts 
of protein were analyzed by anti-HA immunoblot analysis. B) Bar graph represents mean 
[^HJMVA/protein ratios for the experiment in Aj which was performed in duplicate. All ratios 
were normalized to mGBPlwt. 
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CHAPTER 4. GENERAL CONCLUSIONS 
Overview 
The work presented in this dissertation describes the initial characterization of the 
prenylation of murine Guanylate Binding Protein-1 (mGBPl). Based on the amino acid 
sequence of mGBPl and our current understanding of cellular prenylation, this protein should 
be recognized by geranylgeranyl transferase I (GGTase I) and each molecule of mGBPl 
should have a geranylgeranyl isoprenoid covalently attached to its C-terminus. However, our 
experiments with mGBPl both in vivo and in vitro suggest that this protein possesses the 
intrinsic ability to block its own prenylation, and naturally exists in a largely unmodified state. 
This discovery of incomplete prenylation is perhaps the most important finding of the 
dissertation, as it challenges the widely-held belief that prenylation is both automatic and 
stoichiometric for proteins bearing the canonical CaaX motif. That the N-terminal, OTP-
binding region of mGBPl plays a large role in this inhibitory event is also quite interesting, as 
it suggests that this block in modification may be a regulated event in vivo. 
Initial efforts to characterize the basis for the observed poor incorporation of [3H]MVA 
into mGBPl focused on thoroughly exploring, and ultimately excluding, cellular factors other 
than mGBPl itself. Based on the experiments presented in Chapter 2, we tested and discarded 
hypotheses of metabolic and cell type-specific explanations for the deficiency in mGBPl 
prenylation. Expression of mGBPl in cell types other than IFN-treated macrophages did not 
improve its [^H]MVA incorporation. Comparison to other C20-modined proteins in other cell 
types showed that mGBPl itself, and not metabolic issues related to isoprenoid metabolism, 
was the culprit in blocking its own prenylation. Interestingly, work from Chapter 2 led us to 
believe that this deficiency was more severe with respect to GGTase I-mediated prenylation 
than FTase. This transferase specificity provides a foundation for further studies into how 
FTase and GGTase I choose their substrates in vivo. Perhaps a definable region of mGBPl 
will eventually be identified that will explain this transferase-specific defect in prenylation. If 
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so, the inclusion of such elements into new generations of prenyl transferase inhibitors could 
lead to the development of highly specific inhibitors of FTase. 
As mentioned before, a failure in prenylation has been described for some members of 
the Ga family of heterotrimeric signaling proteins. However, these G-proteins possess 
"pseudo CaaXs" which are simply poor substrates for prenylation. In the case of mGBPl, its 
CaaX motif (CTIL) has been shown to be functional on numerous other proteins, including 
two other GBP family members. Thus, the lack of efficient modification of mGBPl is not due 
to a non-functional CaaX. 
We demonstrated in Chapter 2 that non-CaaX amino acids in the C-terminal region of 
mGBPl contribute to mGBPl's prenylation deficiency. Non-CaoX amino acids have been 
shown to promote GGTase I-mediated cross-prenylation of both Gysubunits and Ras proteins 
possessing CIS-type CaaX motifs. However, in each of these cases, prenylation by GGTase I 
was promoted, not impaired, by the CaaX-extrinsic amino acids. Therefore, mGBPl 
represents the first example whereby non-CaaX amino acids actually diminish the capacity for 
prenylation and override the positive signal from the "good" CaaX. 
However, as was shown in Chapter 3, the ability of these non-CaaX amino acids to 
participate in vitiating prenylation by GGTase I relies on participation from N-terminal portions 
of mGBPl. Thus, the unique mechanism that mGBPl uses to hinder its own prenylation 
results from contributions from both N- and C-terminal protein elements. 
Regulation of Prenylation? 
That the region of mGBPl that impairs prenylation includes the GTP-binding domain 
suggests that GTP binding/hydrolysis of mGBPl may potentially regulate prenylation of its C-
terminus. Prenylation of the Rab family of proteins is sensitive to their guanine nucleotide 
state. This is due to a GDP dependence for binding of an accessory factor (REP) necessary for 
preny la t ion  by  GGTase  I I  (Rab  ge rany lge rany l  t r ans fe rase ) .  However ,  bo th  CaaX 
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prenyltransferases identified so far are heterodimers and give no indication that a third subunit 
is required for activity, making a Rab-like scenario for mGBPl unlikely. 
GTP-dependent oligomerization of mGBPl may also be the cause of mGBPl's lack of 
prenylation. Human GBP-1 (hGBPl) as well as the distantly related Mx and dynamin families 
of proteins are known to undergo multimerization. However, we have not been able to 
decisively detect the presence of any higher molecular weight forms of mGBPl that would 
suggest its multimerization. Additionally, we have been unable to detect any mGBPl protein-
protein interactions with itself using the yeast two-hybrid assay. Therefore, while 
oligomerization of mGBPl may be responsible for its block on prenylation in vivo, we 
currently have no evidence to support this. 
Guanine dissociation inhibitors (GDIs) of the Rho family sequester these small 
GTPases into the cytoplasm through simultaneous interaction with the GTP-binding domain 
and prenylated C-terminus. If a similar situation exists with mGBPl, then perhaps a putative 
mGBPl binding partner binds to both the GTP-binding domain as well as the unmodified 
mGBPl C-terminus to preclude efficient geranylgeranylation. Such a mechanism would allow 
for regulated access of the C-terminus for prenylation and could possibly be an integral 
component of mGBPl's biology. 
Biological Signiflcance 
Presently, very little is known regarding the physiological function of the guanylate-
binding proteins. Early studies have shown that in IFN-treated cells, mRNA for GBPs make 
up the most abundant transcripts in interferon-treated cells. Thus, it seems quite likely that 
GBPs play an important role in mediating the cellular effects of IFN. Only one report exists 
regarding possible anti-viral activity for human GBP-1. In that report, no mention is made 
whether the famesyl isoprenoid attached to hGBPl is essential for activity of the protein. 
It is tempting to speculate reasons why mGBPl prevents its own modification. 
Because this virtual absence of isoprenoid appears to be an essential characteristic of mGBPl, 
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it appears likely that selective pressures have created this protein with a fully functional, yet 
grossly-unmodified, CaaX motif. 
Perhaps mGBPl in its unmodified state is actually a suitable partner for the 
aforementioned RhoGDI class of regulatory molecules. In this case, the high levels of GBP 
proteins that accumulate in IFN-treated cells could titrate out interactions of RhoGDI with their 
natural substrates. This would free the Rho/Rac/CDC42 proteins for plasma membrane 
interactions and signaling. 
Alternatively, mGBPl may exist in a non-prenylated state until the proper cellular cue 
(i.e. presence of virus) triggers geranylgeranylation of the mGBPl CaaX. The recoverin and 
ARF proteins are myristoylated proteins who extrude their myristoyl groups using Ca2+- or 
GTP-dependent switch mechanisms respectively (1,2). Perhaps mGBPl undergoes a similar 
switch from a non-prenylated form to a prenylated version required for putative anti-viral 
activity. 
Finally, the lack of mGBPl prenylation could be an adaptive strategy. Perhaps at one 
time, viruses or other pathogens utilized prenylated mGBPl, or another prenylated GBP, to 
their advantage. In this case, the lack of isoprenoid observed on mGBPl could be an attempt 
to thwart pathogenesis through sequestration of pathogen binding to non-prenylated mGBPl. 
Titration of the binding of pathogenic proteins from "good", more efficiendy prenylated GBPs 
necessary for host defense to the non-prenylated mGBPl may be a means by which 
prenylation (or lack thereof) could be playing a crucial role in prevention of disease. 
References 
1. Ames, J. B., R. Ishima, T. Tanaka, J. I. Gordon, L. Stryer, and M. 
Ikura. 1997. Molecular mechanics of calcium-myristoyl switches. Nature 389:198-
202. 
2. Goldberg, J. 1998. Structural basis for activation of ARF GTPase: mechanisms of 
guanine nucleotide exchange and GTP-myristoyI switching. Cell 95:237-248. 
102 
ACKNOWLEDGMENTS 
I would first and foremost like to heartily thank my major professor, Jan Buss, for her 
many years of encouragement, wisdom, guidance, and (most importantly) patience. Though 
my foibles were numerous and frequent, Jan never wavered in her display of faith in my 
abilities. She was also a pillar of strength for me during my father's long, unsuccessful battle 
with cancer. For this, I owe her a debt of gratitude I most certainly will never be able to repay. 
Thus, she has been not only an excellent mentor but also a cherished friend - one whose daily 
company I will miss greatly after I leave Iowa State. 
My wife, Janese O'Brien Stickney, has also been a constant source of support for me 
during my time in graduate school. Not only has she taken a very active part in directly 
assisting me with many of my academic endeavors, but she has served as my ultimate standard 
for how to conduct myself as a person as well as a graduate student. She has earned my 
utmost respect for both her academic abilities as well as her caring and compassionate 
personality, and I am ever grateful for her love and the opportunity to spend my life with her. 
If there are two people responsible for the successes I may experience in life, it is most 
certainly my parents Tom and Joan Stickney. As an only child of more "mature" parents, I 
was quite naturally the focal point of their lives (although they went to great lengths to disguise 
this from me). Through their faith in me and the countless hours they invested in my rearing, I 
was prepared to face the world as an adult with the self-confidence that comes from belief in 
oneself. Their indelible mark on my character will shine brightly for my entire life. 
I must also thank the many students in the Department of Biochemistry, Biophysics, 
and Molecular Biology for their years of companionship. Specifically, Robert Bellin and 
Pierig Lepont have become close friends whose opinions on life and science are invaluable to 
me. I thank you for your many years of friendship and advice. 
I'd also like to thank my many friends outside of the department who have given me 
limitless moral support. Michael Belshan and Aaron Cook and I were members of a rock band 
103 
for a number of years and they will always be cherished friends. Likewise, Michael Sears and 
Shawn Lyons are longtime friends who have shown me that only children can still have 
brothers. Their support and friendship through good times and bad has enriched my life and 
has been a priceless gift to me. 
